

## PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/88379>

Please be advised that this information was generated on 2021-10-24 and may be subject to change.

# Hereditary tubular transport disorders: implications for renal handling of $\text{Ca}^{2+}$ and $\text{Mg}^{2+}$

Henrik DIMKE, Joost G. HOENDEROP and René J. BINDELS

Department of Physiology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands

## ABSTRACT

The kidney plays an important role in maintaining the systemic  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  balance. Thus the renal reabsorptive capacity of these cations can be amended to adapt to disturbances in plasma  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  concentrations. The reabsorption of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  is driven by transport of other electrolytes, sometimes through selective channels and often supported by hormonal stimuli. It is, therefore, not surprising that monogenic disorders affecting such renal processes may impose a shift in, or even completely blunt, the reabsorptive capacity of these divalent cations within the kidney. Accordingly, in Dent's disease, a disorder with defective proximal tubular transport, hypercalciuria is frequently observed. Dysfunctional thick ascending limb transport in Bartter's syndrome, familial hypomagnesaemia with hypercalciuria and nephrocalcinosis, and diseases associated with  $\text{Ca}^{2+}$ -sensing receptor defects, markedly change tubular transport of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$ . In the distal convolutions, several proteins involved in  $\text{Mg}^{2+}$  transport have been identified [TRPM6 (transient receptor potential potential melastatin 6), proEGF (pro-epidermal growth factor) and FXVD2 ( $\text{Na}^+/\text{K}^+$ -ATPase  $\gamma$ -subunit)]. In addition, conditions such as Gitelman's syndrome, distal renal tubular acidosis and pseudohypoaldosteronism type II, as well as a mitochondrial defect associated with hypomagnesaemia, all change the renal handling of divalent cations. These hereditary disorders have, in many cases, substantially increased our understanding of the complex transport processes in the kidney and their contribution to the regulation of overall  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  balance.

## INTRODUCTION


Divalent cations are essential for physiological processes, such as intracellular signalling, enzyme activation, neural

excitability, muscle contraction and bone formation. Overall  $\text{Ca}^{2+}$  balance is regulated via a co-ordinated interplay between the parathyroid glands, bone, intestine and kidneys. Systemic  $\text{Mg}^{2+}$  concentrations are

**Key words:** divalent cation, kidney, hereditary disorder, reabsorption, tubular transport.

**Abbreviations:** BP, blood pressure; BSND, Bartter's syndrome with sensorineural deafness; CaSR,  $\text{Ca}^{2+}$ -sensing receptor; CD, collecting duct; CLC,  $\text{Cl}^-$  channel; CNT, connecting tubule; DCT, distal convoluted tubule; dRTA, distal renal tubular acidosis; EGF, epidermal growth factor; EGFR, EGF receptor; ENaC, epithelial  $\text{Na}^+$  channel; FHH, familial hypocalcaemic hypercalcaemia; FHHNC, familial hypomagnesaemia with hypercalciuria and nephrocalcinosis; FXVD2,  $\text{Na}^+/\text{K}^+$ -ATPase  $\gamma$ -subunit; GFR, glomerular filtration rate; HSH, hypomagnesaemia with secondary hypocalcaemia; IRH, isolated autosomal-recessive hypomagnesaemia; NCC,  $\text{Na}^+-\text{Cl}^-$  co-transporter; NHE3,  $\text{Na}^+/\text{H}^+$  exchanger 3; NKCC2, furosemide-sensitive  $\text{Na}^+-\text{K}^+-2\text{Cl}^-$  co-transporter; NSHPT, neonatal severe primary hyperparathyroidism; OCRL, oculocerebrorenal syndrome of Lowe; PCT, proximal convoluted tubule; PHAI, pseudohypoaldosteronism type II; PST, proximal straight tubule; PTH, parathyroid hormone; ROMK, renal outer medullary  $\text{K}^+$  channel; TAL, thick ascending limb; TRP, transient receptor potential; TRPM, TRP melastin; TRPV, TRP vanilloid; WNK kinase, with-no-lysine kinase; ZO-1, zona occludens-1.

**Correspondence:** Dr René J. Bindels (email r.bindels@ncmls.ru.nl).



**Figure 1** Schematic representation of the nephron listing the predominant origins of intrarenal transport defects causing dysfunctional renal handling of divalent cations

In most species, the transition from the DCT to the CNT is gradual, whereas the transition between these nephron segments in the rabbit is very abrupt. In species where these borders are less well defined with larger segments containing DCT and CNT cells intermingled, the occurrence of the CNT cell is often considered the start of CNT segment [108]. In addition to the CNT cells, intercalated cells involved in acid/base secretion also arise in this segment [108]. Note that defects causing PHAI probably originate from both the DCT and CNT segments, whereas dRTA is caused by disturbed acid/base handling in intercalated cells of the CNT and CD regions. iCD, initial CD; PT, proximal tubules.

maintained in a similar manner; however, the exact mechanisms governing plasma  $Mg^{2+}$  concentrations are less well defined. As essential cellular functions are reliant on maintaining extracellular  $Ca^{2+}$  and  $Mg^{2+}$  concentrations within a narrow range, the consequences of disturbances in these divalent cations often result in symptoms related to instability of the neurological and cardiac systems. Hence hypercalcaemia can lead to fatigue, nausea, coma and abnormal heart rhythms that can result in cardiac arrest [1]. Hypocalcaemia can produce tetany, carpedal spasms and life-threatening arrhythmias [2]. Hypermagnesaemia also causes severe symptoms, including lethargy, coma and cardiac arrest [3]. Similarly, hypomagnesaemia promotes neuromuscular irritability, such as tetany and seizures, as well as cardiac arrhythmias. Secondary hypocalcaemia is also commonly observed in patients with hypomagnesaemia, further complicating their condition [3].

The kidney plays a central role in controlling the excretion of  $Ca^{2+}$  and  $Mg^{2+}$  in response to conditions of deprivation or excess of these cations [4,5]. Transepithelial (i.e. net result of paracellular and transcellular) transport of divalent cations across the epithelia differs in the various nephron segments. Accordingly, the proximal tubule and TAL (thick ascending limb) reabsorb these ions in a passive paracellular manner, whereas in the

distal convolutions active transcellular transport occurs. Many inherited renal diseases related to electrolyte and even protein transport cause defects in the handling of  $Ca^{2+}$  and  $Mg^{2+}$  by the kidney (Figure 1). The aim of the present review is to summarize the current knowledge pertaining to these diseases and how they have contributed to our understanding of renal divalent cation handling.

## PROXIMAL TUBULES

Plasma free/ionized  $Ca^{2+}$  levels are maintained within a narrow range around the set-point value of 1.2 mmol/l [6]. Approx. 50–60% of total plasma  $Ca^{2+}$  is freely diffusible, the majority as ionized  $Ca^{2+}$ , the remaining complexed to other ions. This free portion of the total  $Ca^{2+}$  is filtered by the glomeruli. The remainder is bound to plasma proteins, predominantly albumin, and is largely retained in plasma [7–9]. Of the filtered  $Ca^{2+}$ , only 1–2% is excreted by the kidney, the largest fraction being reclaimed by the renal tubules [7,9]. Detailed micropuncture studies have estimated that approx. 55–60% of the filtered  $Ca^{2+}$  is re-absorbed along the PCT (proximal convoluted tubule). An additional 10% is reabsorbed in the PST (proximal straight tubule) [10–13].

$\text{Ca}^{2+}$  reabsorption in the PCT occurs in proportion to  $\text{Na}^+$  and water. Hence proximal tubular  $\text{Ca}^{2+}$  transport is thought to be primarily passive in nature [14]. The tubule fluid/filterable plasma  $\text{Ca}^{2+}$  ratio has been reported to range from 1.0 to 1.2 along the PCT [11,15]. Thus the isotonic removal of  $\text{Na}^+$  and water from the lumen increases the intraluminal  $\text{Ca}^+$  concentration and facilitates secondary  $\text{Ca}^{2+}$  reabsorption [11,12]. This is in line with the existence of a paracellular shunt pathway, where the electrochemical gradient across the epithelia sets the direction of transport. Importantly, volume expansion (probably by reducing proximal  $\text{Na}^+$  and water reabsorption and, hence, the electrochemical driving force for  $\text{Ca}^{2+}$ ) has been demonstrated to reduce proximal tubular  $\text{Ca}^{2+}$  reabsorption, whereas volume contraction increases the proximal tubular reabsorptive capacity [16].

The systemic  $\text{Mg}^{2+}$  concentration is maintained between 0.75 and 1.0 mmol/l [17]. Approx. 70% of  $\text{Mg}^{2+}$  in serum is freely filterable, either existing as ionized free  $\text{Mg}^{2+}$  or complexed with filterable anions [18]. Thus the concentration of  $\text{Mg}^{2+}$  reached in the initial glomerular filtrate is approx. 0.5 mmol/l [8,19]. The kidney excretes approx. 3–5% of the  $\text{Mg}^{2+}$  found in the ultrafiltrate [20]. Although the PCT has a high permeability to  $\text{Na}^+$  and  $\text{Ca}^{2+}$ , as well as a high tubular reabsorptive capacity for these ions, a limited amount of  $\text{Mg}^{2+}$  (approx. 10–20%) is reabsorbed in this nephron segment [15,19,21]. Similar permeability properties have been reported for the PST [22]. Thus the entire proximal tubule is responsible for reclaiming some 25% of the filtered  $\text{Mg}^{2+}$ . The short half-life of the radioactive  $^{28}\text{Mg}^{2+}$  isotope makes it unsuitable as a tracer and has seriously hampered the experimental determination of  $\text{Mg}^{2+}$  fluxes and permeability coefficients. Hence most determinations of  $\text{Mg}^{2+}$  in tubular punctates have been performed using electron probes, limiting the determinations to net  $\text{Mg}^{2+}$  fluxes. Under these experimental settings, proximal tubular  $\text{Mg}^{2+}$  transport is generally thought to be paracellular. Owing to the apparent permeability differences,  $\text{Na}^+$ -driven water transport increases the intraluminal concentration of  $\text{Mg}^{2+}$  along the proximal tubular epithelium [22,23]. It has been determined that a tubule fluid/filterable  $\text{Mg}^{2+}$  ratio of 1.9 is necessary for  $\text{Mg}^{2+}$  reabsorption to occur in the segment [15]. This suggests that adequate water removal is a prerequisite for  $\text{Mg}^{2+}$  transport to occur and may, therefore, only commence in the late PCT, when the luminal  $\text{Mg}^{2+}$  concentration is sufficiently high [15]. Moreover, the high concentration gradient necessary for transepithelial  $\text{Mg}^{2+}$  transport suggests a poor permeability of the tight junctions to  $\text{Mg}^{2+}$  in the proximal tubule. Interestingly, the proximal reabsorptive capacity in the neonatal rat is much higher, as reabsorption of filtered  $\text{Mg}^{2+}$  ranges between 60 and 70% [24]. Whether this represents a remodelling of the selectivity filter in the tight junction

protein complex during development remains unclear. In contrast with  $\text{Ca}^{2+}$ , volume expansion does not appear to affect proximal tubular  $\text{Mg}^{2+}$  reabsorption [25].


## TRANSPORT DEFECTS OF THE PROXIMAL TUBULE AFFECTING DIVALENT CATION HANDLING

### Dent's disease

Dent's disease is a recessive X-linked proximal tubular disorder associated with low-molecular-mass proteinuria. Males usually present with a more severe phenotype, including aminoaciduria, hypercalciuria, nephrolithiasis, glycosuria and progressive renal failure [26–28]. Individuals with Dent's disease typically have normal plasma  $\text{Mg}^{2+}$  concentrations. Some patients present with rickets, which is normalized after pharmacological 1,25-dihydroxyvitamin  $\text{D}_3$  treatment [26]. In general, patients with Dent's disease have mildly elevated 1,25-dihydroxyvitamin  $\text{D}_3$  levels [26,29]. Thus 1,25-dihydroxyvitamin  $\text{D}_3$  may serve to stabilize plasma  $\text{Ca}^{2+}$  levels secondary to renal  $\text{Ca}^{2+}$  wasting or elevated 1,25-dihydroxyvitamin  $\text{D}_3$  levels may by itself augment the hypercalciuria [29].

Dent's disease is caused by mutations in the *CLC5* gene [28]. *CLC5*, originally identified as a  $\text{Cl}^-$  channel, is also known to function as a lysosomal  $\text{Cl}^-/\text{H}^+$  antiporter involved in endosomal acidification [30,31]. *CLC5* localizes to the proximal tubule, the TAL and the CD (collecting duct) intercalated cells [32]. Genetic ablation of *Clc5* in mice impairs proximal tubular endocytosis of proteins by inhibiting the trafficking of megalin and cubilin [33–35], largely explaining the low-molecular-mass proteinuria. Similarly, aminoaciduria and glycosuria may occur due to defective trafficking of the transport proteins responsible for proximal tubular reabsorption of these solutes [36]. It is important to note that two different mice strains have been generated with a targeted deletion of *Clc5* [34,35]. Although many of the renal phenotypic characteristics observed in Dent's disease are present in both mice, important differences are observed in terms of hypercalciuria, 1,25-dihydroxyvitamin  $\text{D}_3$  levels, nephrocalcinosis and renal failure (reviewed in detail in [37]). Thus, currently, the exact underlying mechanism responsible for hypercalciuria remains to be clarified.

Interestingly, a kidney-specific deletion of megalin (*Lrp2*) in mice causes hypocalcaemic hypercalciuria, vitamin D deficiency and extrarenal symptoms such as rickets [38,39]. The inactive vitamin D precursor 25-dihydroxyvitamin  $\text{D}_3$ , complexed to the vitamin D-binding proteins, has been shown to be reabsorbed in the proximal tubules by the endocytic receptor megalin [39]. Thus megalin-mediated uptake of inactive 25-dihydroxyvitamin  $\text{D}_3$  by the proximal tubule appears a



**Figure 2** Schematic representation of the cellular composition of renal ion and water transport proteins within the various nephron segments

The iCD (initial CD) represents the start of the CD principal cells arising in the late distal convolutions. The CNT and the iCD principal cells express TRPV5, as does NCC-expressing cells in the DCT2 segment in many species [118–121]. The DCT cell portrayed in the Figure resembles one located in the early DCT region. Transepithelial voltages are listed for the PT [204], TAL [55,56], although the transepithelial voltage may increase to approx. +30 mV [57–59], DCT [55,10,111] and CNT [109]. AQP, aquaporin; PTHR, PTH receptor; ATP6B1 (ATP6V1B1), B1 subunit of  $H^+$  ATPase; ATP6N1B (ATP6V0A4), 116 kDa subunit a isoform 4 of  $H^+$  ATPase; PT, proximal tubules.

prerequisite for conversion into its active form 1,25-dihydroxyvitamin  $D_3$ . However, it is currently unknown whether this mechanism contributes to hypercalciuria in Dent's disease, as impaired uptake is not reflected in the serum 1,25-dihydroxyvitamin  $D_3$  concentrations. Whether ablation of the transporter in more distal segments promotes hypercalciuria remains untested.

### OCRL (oculocerebrorenal syndrome of Lowe)

OCRL is an X-linked disease caused by mutations in *OCRL1*, which encodes an inositol polyphosphate 5-phosphatase [40]. Affected males have congenital cataracts, mental retardation and renal tubular dysfunction. Evidence suggests that *OCRL1* protein deficiency can impair lysosomal trafficking in the proximal tubule via accumulation of the substrate phosphatidylinositol 4,5-bisphosphate [41,42]. Thus, similar to Dent's disease, massive low-molecular-mass proteinuria as well as other characteristics of proximal tubular dysfunction are observed. Additionally, renal tubular acidosis is often detected in patients with Lowe's syndrome. Individuals suffering from the syndrome only infrequently display normocalcaemic hypercalciuria and calcifications [43]. Strikingly, patients have also been identified with

mutations in *OCRL1* that develop an isolated renal Dent's disease-like phenotype with hypercalciuria, but without tubular acidosis and extrarenal symptoms, such as cataracts and neurological abnormalities [44]. It is currently unknown how mutations in a single gene can cause two supposedly distinct phenotypes.

### TAL

Micropuncture experiments have demonstrated that approx. 20–25% of the filtered  $Ca^{2+}$  and 60% of filtered  $Mg^{2+}$  is reabsorbed in the TAL [10,11,45]. In this segment, the transport of divalent cations occurs in a passive paracellular manner. In most species, the cortical TAL appears to be most important for paracellular transport, as medullary transport is negligible under basal conditions [46–49]. The lumen-positive transepithelial voltage appears to be the most important driving force for  $Ca^{2+}$  and  $Mg^{2+}$  reabsorption. Furosemide, a potent inhibitor of  $Na^+$ ,  $K^+$  and  $Cl^-$  co-transport, almost completely abolishes the transepithelial voltage gradient across the TAL [50–52]. Under these conditions,  $Ca^{2+}$  and  $Mg^{2+}$  transport is drastically inhibited [53,54]. As shown in Figure 2, NKCC2 (furosemide-sensitive  $Na^+$ – $K^+$ – $2Cl^-$  co-transporter) serves as the apical entry mechanism

for  $\text{Na}^+$ ,  $\text{K}^+$  and  $\text{Cl}^-$  in the TAL. Similarly, ROMK2 (renal outer medullary  $\text{K}^+$  channel 2) is necessary for apical  $\text{K}^+$  recycling across the apical membrane. Inwardly transported  $\text{Cl}^-$  exits across the basolateral membrane, predominantly via CLC-Kb channels. The  $\text{Na}^+/\text{K}^+$ -ATPase constitutes the initial driving force for  $\text{Na}^+$  transport in the TAL. Other transporters involved in vectorial  $\text{Na}^+$  transport have also been identified [i.e. NHE3 ( $\text{Na}^+/\text{H}^+$  exchanger 3)] in the medullary TAL. However, their exact contribution to overall  $\text{Na}^+$  transport within the loop is unclear.

The generation of a lumen-positive transepithelial voltage drives the paracellular reabsorption of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  from the lumen. The electric gradient is likely to be made up of two mechanisms. NKCC2-mediated uptake of  $\text{Na}^+$ ,  $\text{K}^+$  and two  $\text{Cl}^-$  ions coupled with the subsequent secretion of  $\text{K}^+$  across the apical membrane generates a lumen-positive voltage of approx. 5–10 mV [55,56]. Secondly, reabsorption of  $\text{Na}^+$  along the length of the TAL reduces the intraluminal  $\text{Na}^+$  concentration. Under these conditions, backflux of  $\text{Na}^+$  from the interstitium to the tubular lumen may further augment voltage to values of approx. 30 mV [57–60].

cAMP-elevating hormones such as PTH (parathyroid hormone) stimulate  $\text{Na}^+/\text{Cl}^-$  transport in the TAL, probably by modulating these transport processes [49,61]. Interestingly, after application of PTH, changes in net  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  transport appear much higher than the concomitant changes reported in the transepithelial voltage. These observations suggest that alterations in the permeability of the paracellular pathway can modulate transepithelial divalent cation transport [61]. Similarly, CaSR ( $\text{Ca}^{2+}$ -sensing receptor) is expressed in the basolateral membrane of the TAL, where it modulates transport in response to changes in extracellular divalent cations [62,63]. Here activation of CaSR can inhibit vasopressin-induced cAMP formation by as much as 90% [64]. Conversely, *in vitro* microperfusion experiments have shown that activation of the receptor inhibits net transport of  $\text{Ca}^{2+}$ , while leaving the transepithelial voltage and net  $\text{Na}^+/\text{Cl}^-$  flux intact [64,65]. However, chronic stimulation of the receptor is likely to reduce NKCC2 abundance as its expression is stimulated by cAMP. This is observed in rats administered gentamycin, an aminoglycoside antibiotic that activates CaSR [66,67]. In contrast, some reports have suggested that pharmacological inhibition of transepithelial voltage does not substantially affect  $\text{Ca}^{2+}$  transport in the TAL, which is suggestive of a transcellular pathway [48,65,68]. The nature of this transcellular route remains poorly defined, although it can presently not be excluded. Why only 20–25% of the filtered  $\text{Ca}^{2+}$  is reabsorbed in the TAL, whereas as much as 60% of filtered  $\text{Mg}^{2+}$ , is not entirely clear, but may represent differences in either delivery of divalent cations to the bend of Henle's loop or permeability differences for divalent cations within the TAL.

## TRANSPORT DEFECTS OF THE TAL AFFECTING DIVALENT CATION HANDLING

### Bartter's syndrome

Bartter's syndrome is characterized by severe renal  $\text{Na}^+/\text{Cl}^-$  wasting, hypokalaemic metabolic alkalosis, hyperreninaemia, hyperaldosteronism and prostaglandin  $\text{E}_2$  hypersecretion, and patients present with a normo- or hypo-tensive phenotype [69–71]. Most gene defects causing Bartter's syndrome are inherited in an autosomal-recessive manner. Mutations in the genes encoding NKCC2 (*SLC12A1*) or ROMK (*KCNJ1*) lead to antenatal Bartter's syndrome [72,73]. Defects in either protein severely impair transport function in the TAL, produce renal  $\text{Na}^+/\text{Cl}^-$  wasting and dilute the interstitial gradient, resulting in a pronounced urinary concentrating defect. Thus antenatal Bartter's syndrome is the most severe form of Bartter's syndrome, being evident prenatally with polyhydramnios and often premature birth. Post-natally, severe polyuria causes volume depletion/dehydration and fever. Marked hypercalciuria, secondary nephrocalcinosis and osteopenia are hallmark features of antenatal Bartter's syndrome [71]. Interestingly, hypermagnesuria and hypomagnesaemia are not common characteristics of this type of Bartter's syndrome. CLC-Kb is a basolateral  $\text{Cl}^-$  channel located in the TAL, as well as more distal nephron segments [74]. In comparison with the apical entry and recycling mechanisms, CLC-Kb appears not to be the sole efflux pathway for  $\text{Cl}^-$  in the TAL. Accordingly, the  $\text{K}^+-\text{Cl}^-$  co-transporter and potentially other  $\text{Cl}^-$  channels located in the TAL may participate in removing intracellular  $\text{Cl}^-$  [75,76]. As suggested by Konrad et al. [75], the level of compensation provided by these efflux pathways may explain why the clinical definition is highly variable in patients with recessive *CLCNKB* (the gene encoding CLC-Kb) defects [75]. Thus individuals with CLC-K dysfunction and, hence, classical Bartter's syndrome can present with an antenatal Bartter's-syndrome-like phenotype to being almost asymptomatic [75,77]. In contrast with patients with antenatal Bartter's syndrome, hypercalciuria and nephrocalcinosis are an uncommon feature in these individuals; however, hypomagnesaemia occurs in up to 50% of affected individuals [75,77]. Recessive mutations in *BSND* (Bartter's syndrome with sensorineural deafness; encoding Barttin, a  $\beta$ -subunit necessary for CLC-Kb function) lead to perhaps the most severe form of antenatal Bartter's syndrome, with sensorineural deafness and associated chronic renal failure [78,79]. In line with this, defects in both CLC-Ka and CLC-Kb confer a phenotype identical with that reported for *BSND* Barttin) mutations [80]. In contrast with CLC-Kb defects, mutations in *BSND* do not result in hypomagnesaemia. The absence of renal  $\text{Mg}^{2+}$  wasting has been attributed to the low GFR (glomerular filtration rate) often observed in *BSND*, paralleling the decline in

renal function. Nephrocalcinosis is not a common feature of this disease [81].

Autosomal-dominant hypocalcaemic hypercalciuria is observed in patients with activating mutations in *CASR* (the gene encoding CaSR) [82,83]. Patients generally present with mild asymptomatic hypocalcaemia, and with serum  $Mg^{2+}$  and PTH levels in the lower-to-normal range [82]. Functional analysis of these mutant receptors revealed a left-shift in the dose–response curve; thus lower  $Ca^{2+}$  concentrations increase half-maximal activity of the receptor [82,83]. Some activating mutations appear to be more severe in changing the responses to extracellular  $Ca^{2+}$  and, thus, lead to an autosomal-dominant form of Bartter's syndrome [62,83,84]. These patients present with a phenotype similar to classical Bartter's syndrome, but with hypocalcaemia, suppressed secretion of PTH, renal  $Ca^{2+}$  wasting and nephrocalcinosis. Hypomagnesaemia and hypermagnesuria have also been reported in these patients [62,84].

It is interesting to note that, although all of the Bartter's syndrome types described are caused by inhibition of TAL transport and full or partial dissipation of the electrochemical gradient, there is a considerable variability in the consequence for the handling of divalent cations. Several theories have been presented to explain this diversity; however, the exact reasons for these controversies still remain largely enigmatic. Less  $Na^+$  loss is reported in most patients with Bartter's syndrome with CLC-Kb defects (in comparison with antenatal Bartter's syndrome), which often show a less severe phenotype and also a decreased prevalence of hypercalciuria and secondary nephrocalcinosis. It is difficult to directly envision the electrochemical gradients for  $Mg^{2+}$  and  $Ca^{2+}$  in the TAL of patients with Bartter's syndrome, as both volume depletion and polyuria will affect both systemic and tubular concentrations, and probably provoke compensatory mechanisms. However, it is probable that renal  $Na^+$  wasting is less severe in patients with Bartter's syndrome with CLC-Kb defects and, therefore, that the lumen-positive voltage is less affected. This may explain why these patients rarely present with hypercalciuria compared with individuals with antenatal Bartter's syndrome. Unfortunately, no clear correlation between urinary  $Na^+$  and  $Ca^{2+}$  wasting has been presented in individuals with Bartter's syndrome. Thus additional phenotypic characterization of factors affecting  $Ca^{2+}$  wasting in Bartter's syndrome might elucidate this.

Why the opposite relationship is observed for renal  $Mg^{2+}$  handling between the Bartter's syndromes is also unclear. The low prevalence of hypermagnesuria in antenatal Bartter's syndrome suggests an enormous compensatory capacity of the DCT (distal convoluted tubule). In addition, patients with mutations in *CLCNKB* have a higher prevalence of hypermagnesuria. The expression of CLC-Kb has been reported to be the highest in the DCT

[74]. Some patients with *CLCNKB* mutations present with a mixed Bartter's syndrome/Gitelman's syndrome phenotype with hypomagnesaemia [85]. Hence loss of CLC-Kb in segments distal to the TAL may contribute to this phenotype. The potential mechanism whereby this occurs is not known.

### **FHHNC (familial hypomagnesaemia with hypercalciuria and nephrocalcinosis)**

Patients with the autosomal-recessive disorder FHHNC often develop severe hypomagnesaemia, due to a grossly increased fractional renal excretion of  $Mg^{2+}$ . Similarly, affected individuals have hypercalciuria, although systemic concentrations of  $Ca^{2+}$  are within the normal range [86,87]. Bilateral nephrocalcinosis is observed in all patients, and the severity of this finding is correlated with the progression of renal insufficiency. Ultimately, this leads to chronic renal failure. The primary problem is renal in origin, which is supported by the observation that affected individuals after renal transplantation normalize their plasma  $Mg^{2+}$  concentrations and return to a normocalciuric state [87].

Originally identified by Simon et al. [88], a defect in *CLDN16*, the gene encoding the tight junction protein claudin-16 (also known as paracellin-1), is now known to be the underlying cause of FHHNC [88]. Initial hydrophobic cluster analysis indicated that claudin-16 forms four transmembrane domains with intracellular C- and N-termini. The protein was found to localize to the tight junctions of the TAL, as well as the DCT [88–90], suggesting a possible role for claudin-16 in regulating the paracellular permeability to divalent cations. The mutations described often encode a single amino acid substitution in the transmembrane or extracellular domains of claudin-16, probably rendering the protein non-functional [88,91]. Another mutation in *CLDN16* has been reported, which confers a less severe phenotype with regression of the hypercalciuria and maintenance of the GFR. The mutation, which is found within a putative PDZ domain, appears predominantly to prevent the binding of claudin-16 to ZO-1 (zona occludens-1) and causes mislocalization of the protein to lysosomes [92]. Although the regulation of claudin-16 remains incompletely understood, phosphorylation of claudin-16 at Ser<sup>217</sup> via the cAMP/PKA (protein kinase A) pathway appears to confer regulation by localizing claudin-16 to the tight junctions [93]. This is to some degree compatible with the observation that the cAMP-elevating hormone PTH can change the permeability of the paracellular pathway to  $Ca^{2+}$  and  $Mg^{2+}$  [61].

Individuals with a similar phenotype to patients with mutations in *CLDN16* have been described [89]. Affected individuals had severe hypomagnesaemia due to renal  $Mg^{2+}$  losses, in addition

to bilateral nephrocalcinosis and renal insufficiency. The disease in these individuals was complicated by severe ocular problems, contrasting with infrequent milder ocular problems observed in patients with *CLDN16* mutations. Patients were found to have mutations in the *CLDN19* gene, which encodes claudin-19 in the same family of tight junction proteins. Complete co-localization with claudin-16 was found within the kidney [89], implicating a role in divalent ion homeostasis.

Expressing claudin-16 in cells has generated highly variable results in terms of cation permeability (reviewed by [94]). When claudin-16 is expressed in LLC-PK1 cells, a high permeability for  $\text{Na}^+$  is observed, while the  $\text{Cl}^-$  flux remains unaffected. Moreover, the permeability for  $\text{Mg}^{2+}$  was much smaller than that observed for  $\text{Na}^+$  [59]. In the same cells, claudin-19 expression decreased absolute permeability to  $\text{Cl}^-$ , without affecting the  $\text{Na}^+$  permeability [95]. When co-expressed, the tight junction becomes selective for cations [95]. This is in line with studies reporting a paracellular shunt pathway for  $\text{Na}^+$  in the cortical TAL that is cation selective [57,96]. Expression of FHHNC-causing mutants of claudin-16 reduced selectivity for cations in LLC-PK1 cells [59]. Similarly, mutations in claudin-19 decreased its ability to block  $\text{Cl}^-$  permeation, leaving  $\text{Na}^+$  permeability intact [95]. It remains unclear whether  $\text{Mg}^{2+}$  even permeates these claudins in sufficient degree to support the massive reabsorptive capacity for this ion in the TAL [59,94]. Using RNA interference, depletion of claudin-16 in mice also confers an FHHNC-like phenotype. Interestingly, microperfusion studies demonstrated that these mice have a 50% reduction in the paracellular cation selectivity of the TAL ( $P_{\text{Na}}/P_{\text{Cl}}$ ) [97]. Furthermore, no change in the selectivity between  $\text{Na}^+$  and  $\text{Mg}^{2+}$  was found ( $P_{\text{Na}}/P_{\text{Mg}}$ ), suggesting that claudin-16 functions predominantly as a non-selective cation channel [97].

How can changes in paracellular  $\text{Na}^+$  fluxes explain the aetiology of FHHNC? On the basis of studies by Hou, Goodenough and co-workers [59,95], it is suggested that mutations in claudin-16 or claudin-19 in FHHNC would increase the permeability of the tight junction to anions, promote backflux of proportionally more  $\text{Cl}^-$ , and thereby dissipate the transepithelial voltage gradient. One would also expect some sort of  $\text{Na}^+/\text{Cl}^-$  wasting to occur in the TAL; however, patients with FHHNC due to a defective *CLDN16* gene retain their ability to conserve urinary  $\text{Na}^+$  after  $\text{Na}^+/\text{Cl}^-$  deprivation, have normal aldosterone levels and have appropriate natriuretic responses to furosemide. Yet, their calciuretic and magnesiuretic response to furosemide is severely blunted [98]. Conversely, in the *Cldn16*-depleted mice, lowered BP (blood pressure), an increase in the urinary  $\text{Na}^+/\text{K}^+$  ratio and elevated aldosterone levels are observed, along with enhanced CD  $\text{Na}^+$  transport [97,99].

### **Familial benign hypercalcaemia and NSHPT (neonatal severe primary hyperparathyroidism)**

Inactivating mutations in *CASR* have been identified in hypercalcaemic patients with FHH (familial hypocalciuric hypercalcaemia) and a severe neonatal form of primary hyperparathyroidism (NSHPT). Although FHH is inherited in an autosomal-dominant fashion, NSHPT is caused by homozygous inactivating mutations in *CASR*. Patients with FHH can have hypercalcaemia and hypermagnesaemia, while an inappropriate reduction in urinary  $\text{Ca}^{2+}$  excretion is observed. A lower renal excretion of  $\text{Mg}^{2+}$  has also been reported in FHH [100]. Moreover, serum PTH concentrations are often found within the normal range, in the presence of hypercalcaemia, or even elevated levels have been reported in a subset of patients [101]. Thus inactivating mutations in the *CASR* allele shifts the set point of  $\text{Ca}^{2+}$  in this condition, blunting the normal ability to reduce PTH secretion in response to elevated  $\text{Ca}^{2+}$  levels and by directly increasing renal  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  reabsorption [63,102–104]. Although patients with FHH can have lifelong hypercalcaemia and hypermagnesaemia, they are generally asymptomatic [104]. In NSHPT, homozygous inactivation of the *CASR* gene cause infantile hyperparathyroidism. This rare disorder is life-threatening, with severe hypocalciuric hypercalcaemia. Many extrarenal symptoms associated with hypercalcaemia are observed. In addition, polyuria and dehydration is commonly reported [63,105]. Renal hyperabsorption of divalent cations is partly caused by increased PTH levels, resulting from reduced suppression of PTH secretion in the CaSR-impaired parathyroid. In addition, an intrinsic mechanism due to reduced functionality or an absence of CaSR in the TAL occurs independently of PTH [106]. This becomes evident in *Casr*-deficient mice, as their lethal phenotype normally observed after deletion of the *Casr* gene can be rescued by crossing these mice with mice deficient in *Pth*. However, in these double-knockout mice with a complete absence of circulating PTH, the variance of serum  $\text{Ca}^{2+}$ , as well as the fractional excretion of  $\text{Ca}^{2+}$ , exceeded the variance observed in *Pth*-deficient mice with an intact CaSR [107]. These results suggest that CaSR is important in regulating  $\text{Ca}^{2+}$  homeostasis also independently of regulating PTH secretion.

### **DCT, CNT (CONNECTING TUBULE) AND INITIAL CDs**

The distal convolutions are often defined as comprising the DCT, CNT and the initial CD [108]. Several species differences can be observed in the composition and borders of the individual nephron segments, particularly between rabbit compared with human, mice



and rat. Although the transition between the different nephron segments ends abruptly in the rabbit, the borders between these segments are more intermingled in the other species. Lumen negative transepithelial voltage increases from approx.  $-5$  mV in the early convolutions up to approx.  $-40$  mV or more towards the end of the late convolutions [109–113]. However, some variability in the measured voltages have been reported [109]. Detailed micropuncture studies have estimated that approx. 3–7% of the filtered  $\text{Ca}^{2+}$  is reclaimed between the early or late distal sites and the final urine in the rat [10,19,114]. However, the absence of direct determinations of delivery in juxtamedullary nephrons may only provide approximate estimates. It is unclear whether these punctures represent the whole  $\text{Ca}^{2+}$ -transporting segment in the distal convolutions. Approx. 2% of the filtered load is reabsorbed between early and late distal collections in the same nephron, whereas the amount doubles in the presence of PTH [115].  $\text{Ca}^{2+}$  reabsorption is essentially thought to be active, as it occurs in the presence of lower intraluminal  $\text{Ca}^{2+}$  concentrations and lumen negative transepithelial voltages [10].

The TRPV5 [TRP (transient receptor potential) vanilloid 5] channel provides the main apical entry step for  $\text{Ca}^{2+}$  in the distal convolutions. TRPV5 was originally cloned from primary cultures of rabbit renal CNT/cortical CD tubules [116]. The channel localizes primarily to the CNT in the rabbit [117,118]. In other rodents, expression of TRPV5 is found in the DCT2 segment [expressing NCC ( $\text{Na}^+$ – $\text{Cl}^-$  co-transporter) and ENaC (epithelial  $\text{Na}^+$  channel)], the CNT and the initial CD [118–121]. The channel co-localizes with the  $\text{Ca}^{2+}$ -binding protein calbindin- $\text{D}_{28\text{K}}$  and the basolateral extrusion proteins PMCA1b (plasma membrane ATPase 1b) and NCX1 ( $\text{Na}^+$ / $\text{Ca}^{2+}$  exchanger type 1). Transgenic mice lacking TRPV5 have augmented renal  $\text{Ca}^{2+}$  loss, and micropuncture studies effectively demonstrate that  $\text{Ca}^{2+}$  reabsorption in the distal convolutions is disturbed [122]. Several studies have shown TRPV5 as an essential constituent in transcellular  $\text{Ca}^{2+}$  reabsorption and it is, therefore, surprising that no monogenic disorders or polymorphisms have been identified thus far [123].

Detailed physiological measurements suggest that the distal convolutions are responsible for reabsorbing 5–6% of the filtered  $\text{Mg}^{2+}$  [19,124]. Again, these values were determined by subtracting the delivery of ions to the distal sites and the final urine. Similar experiments have reported that approx. 8% of the filtered load is reabsorbed between the early and late distal collections [115]. Brunette et al. [124] suggested that, on the basis of their early and late distal micropuncture results, reabsorption of  $\text{Mg}^{2+}$  is localized in the early portion rather than along the whole distal tubule, thus, predominantly in the DCT. The early distal tubule constitutes

a high-resistance epithelium with a lumen negative voltage of approx.  $-5$  mV [55,110,111]. Moreover, the transepithelial movement of  $\text{Mg}^{2+}$  appears to be unidirectional. These observations support the presence of active transcellular  $\text{Mg}^{2+}$  transport in this segment [125]. This is corroborated further by the observation that the luminal  $\text{Mg}^{2+}$  concentration in the DCT ranges between 0.2 and 0.7 mmol/l [4], while that of the cell is maintained approx. 0.2–1.0 mmol/l [126,127]. Under these conditions, uptake of  $\text{Mg}^{2+}$  across the apical membrane would be dictated largely by the negative intracellular membrane potential found in the DCT cell [128,129]. In addition, distal reabsorption of  $\text{Mg}^{2+}$  appears to be load-dependent, as increasing delivery augments reabsorption [54,125]. Cellular influx of  $\text{Mg}^{2+}$  probably occurs through the TRPM6 (TRP melastin 6) channel, a channel selective for divalent cations [130]. TRPM6 is structurally similar to other TRP channels with six transmembrane segments. Only shared with TRPM7 is the unique  $\alpha$ -kinase domain fused to the C-termini [131]. It is worth noting that the current debate questions whether TRPM6 functions as a homo-tetramer. Distinctive properties of functional homomeric TRPM6 channels, as well as TRPM6/TRPM7 heteromeric channels, have been recorded [132]. In addition, several groups have reported the electrophysiological characteristics of TRPM6 in mammalian cells without simultaneously expressing TRPM7 [130,132,133]. In contrast with these observations, others have reported that TRPM7 expression is necessary for localization at the plasma membrane and for the generation of TRPM6 currents [134–137]. Thus the exact molecular composition of the  $\text{Mg}^{2+}$  influx pathway in transporting epithelia remains to be determined. *Trpm6* mRNA expression was restricted to the kidney, lung and intestine (with the highest abundance in colon and caecum of mice) [138,139]. Immunohistochemical localization of the channel has been reported, where TRPM6 was restricted to the apical membrane domains of renal DCT cells [130]. Intracellular carrier proteins and basolateral excursion mechanisms are yet to be identified.

## TRANSPORT DEFECTS OF THE DCT AFFECTING DIVALENT CATION HANDLING

### HSH (hypomagnesaemia with secondary hypocalcaemia)

*TRPM6* was originally identified as the causative gene of the autosomal-recessive disorder known as HSH [139,140]. Individuals suffering from HSH present in early infancy with symptoms related to neuromuscular excitability, such as muscle spasms, tetany and generalized convulsions [141]. These symptoms probably occur as a consequence of a severe fall in plasma  $\text{Mg}^{2+}$  and  $\text{Ca}^{2+}$  concentrations. Symptoms can be reduced

by high dose  $\text{Mg}^{2+}$  administration. Interestingly, this  $\text{Mg}^{2+}$  supplementation normalizes the plasma  $\text{Ca}^{2+}$  concentration, while plasma  $\text{Mg}^{2+}$  remains subnormal [142]. A patient with HSH had a failure to effectively absorb  $\text{Mg}^{2+}$  from low intraluminal intestinal  $\text{Mg}^{2+}$  concentrations [143]; however, the patient with HSH had a positive  $\text{Ca}^{2+}$  balance, excluding a common defect in  $\text{Mg}^{2+}$  and  $\text{Ca}^{2+}$  transport mechanisms. These results support a role for TRPM6 in saturable active  $\text{Mg}^{2+}$  transport, serving as an apical entry mechanism for  $\text{Mg}^{2+}$  in the enterocyte. Although the hypomagnesaemia in HSH appears to be primarily the result of malabsorption of  $\text{Mg}^{2+}$  in the intestine, there is also a serious, although not well studied, renal  $\text{Mg}^{2+}$  leak. Patients with HSH have been reported to have either normal renal  $\text{Mg}^{2+}$  conservation [142–144] or an additional renal  $\text{Mg}^{2+}$  leak [139,140,145]. However, when an intravenous  $\text{Mg}^{2+}$  load was administered to patients with HSH, renal wasting was clearly noticeable [140]. Thus these individuals waste urinary  $\text{Mg}^{2+}$  at a lower plasma concentration than normal individuals do. Agus [146] has described previously that maintaining a fractional  $\text{Mg}^{2+}$  excretion above 2% in the presence of hypomagnesaemia should be considered a renal leak in itself. This is corroborated by a report showing an inappropriately high fractional excretion given severe hypomagnesaemia in patients with HSH [139].

### IRH (isolated autosomal-recessive hypomagnesaemia)

This rare form of hypomagnesaemia was initially described in two siblings who presented with low serum  $\text{Mg}^{2+}$  concentrations and an inappropriately high fractional excretion of  $\text{Mg}^{2+}$  [147]. In addition, these individuals suffered from psychomotor retardation during their youth and are presently suffering from moderate mental retardation and epileptic seizures [147,148]. Thus these observations indicated a potential defect largely related to renal  $\text{Mg}^{2+}$  transport, similar to that observed for  $\text{Mg}^{2+}$ -loaded patients with HSH. Interestingly, there were no observable secondary changes in the handling of  $\text{Ca}^{2+}$  [147], which may to some extent explain why these patients are devoid of tetany. Detailed homozygosity mapping approaches and direct sequencing revealed that these sisters had a mutation in the *EGF* (epidermal growth factor) gene, causing a defect in the routing of the pro-EGF to the basolateral plasma membrane [148]. This mutation resulted in impaired autocrine/paracrine secretion of EGF to the interstitium, thereby inhibiting the activation of basolateral EGFRs (EGF receptors) in the DCT. Subsequent patch-clamp analysis and classical biochemical experiments showed that application of EGF activates TRPM6 and shuttles it from endomembrane compartments to the membrane [148,149]. Interestingly, inhibition of the EGFR by cetuximab, a monoclonal

anticancer drug, causes pronounced hypomagnesaemia in colorectal cancer patients [148,150]. Unlike patients with impaired sorting of the EGF protein, cetuximab treatment produces secondary hypocalcaemia in patients with moderate-to-severe hypomagnesaemia (grade 2 or higher), probably resulting from impaired PTH secretion [150]. Similarly, patients with severe hypomagnesaemia did show signs of fatigue and cramps. IRH and related inhibition of the EGFR by cetuximab diverges from HSH in several of the phenotypic characteristics, suggesting perhaps additional effects of EGF on  $\text{Mg}^{2+}$  handling. Incubation of TRPM6-expressing cells with cetuximab completely abolishes the EGF-induced increases in channel currents [149]. Unlike TRPM6, the current literature suggests that TRPM7 is not activated by EGF and thus appears to be an unlikely target [149]. Whether other transporters are involved in conferring hypomagnesaemia in IRH remains to be defined. Taken together, these results indicate that EGF is a novel magnesium-tropic factor acting primarily to increase renal  $\text{Mg}^{2+}$  reabsorption.

### Isolated dominant hypomagnesaemia

This form of hypomagnesaemia was characterized in two unrelated families [151]. Affected individuals showed isolated renal  $\text{Mg}^{2+}$  wasting, as the renal reabsorption of  $\text{Mg}^{2+}$  remained within the normal range in the presence of hypomagnesaemia. The only other observable renal symptom was a lowered excretion of  $\text{Ca}^{2+}$  in the urine [151]. The underlying defect was later described to be a G41R mutation in the *FXFD2* gene, the so-called  $\text{Na}^+/\text{K}^+$ -ATPase  $\gamma$ -subunit. FXFD proteins are a family of single transmembrane proteins known to modulate  $\text{Na}^+/\text{K}^+$ -ATPase function. The exact intrarenal localization of the FXFD2 protein is controversial, although some reports suggest that it localizes to the DCT [152–155]. The FXFD2 protein changes the  $\text{Na}^+/\text{K}^+$ -ATPase kinetics by reducing the affinity for  $\text{Na}^+$  while increasing that for  $\text{K}^+$  [152,156,157]. FXFD2 G41R proteins have been shown to oligomerize, similar to the wild-type subunit. However, although FXFD2 localizes to the cytoplasm and the plasma membrane, the G41R mutant is retained in the cell. Thus it is suggested that the dominant-negative FXFD2 G41R protein would oligomerize with wild-type FXFD2 proteins, retaining them inside the cell unable to bind and activate the other  $\text{Na}^+/\text{K}^+$ -ATPase subunits [158,159]. Thus the current hypothesis states that reducing outward basolateral  $\text{Na}^+$  transport in the polarized DCT cell reduces the intracellular voltage, thereby reducing the inward electric driving force for  $\text{Mg}^{2+}$  potentially through TRPM6. Interestingly, mice with a targeted disruption of the *Fxyd2* gene have no change in the urinary excretion of  $\text{Mg}^{2+}$  or serum  $\text{Mg}^{2+}$  concentrations [154]. The absence of hypomagnesaemia is also observed by heterozygous deletion of the entire *FXFD2* gene in humans, indicating

that renal  $Mg^{2+}$  loss in this disease is due to a dominant-negative nature of the G41R mutation, rather than haploinsufficiency [158]. A recent report [160] suggests a potential role for FXVD2 as an inward rectifying channel, which differs from that of the FXVD2 G41R mutant. Moreover, the authors speculate that the FXVD2 protein can be involved in the basolateral extrusion of  $Mg^{2+}$  from the cell [160]. The exact role of the  $\gamma$ -subunit in regulating renal  $Mg^{2+}$  reabsorption remains to be clarified experimentally.

### **Gitelman's syndrome**

Gitelman's syndrome is a salt-losing disorder characterized by hypokalemic metabolic alkalosis, hypomagnesaemia and hypocalciuria [161]. Renin activity and aldosterone concentrations are elevated, but only marginally in comparison with patients with Bartter's syndrome. The disorder is autosomal-recessive and is caused by mutations in *SLC12A3*, which encodes the thiazide-sensitive NCC [162]. The Gitelman's phenotype is mimicked by chronic thiazide treatment, a potent blocker of NCC [163,164]. The hypocalciuric effect of *SLC12A3* gene deletion or chronic thiazide administration is probably due to hypovolaemia, although some reports have suggested an additional direct effect on  $Ca^{2+}$  reabsorption in the distal convolutions [165,166]. Volume contraction causes secondary increases in proximal tubular  $Na^+$  transport and, thus, facilitates paracellular hyperabsorption of  $Ca^{2+}$ . This is supported by several observations. Micropuncture studies in mice with genetic ablation of the *Slc12a3* gene had a reduced delivery of  $Na^+$  and  $Ca^{2+}$  to the late proximal tubule, consistent with increased  $Na^+$  and  $Ca^{2+}$  reabsorption in the proximal tubule. In addition, these micropuncture experiments indicated that  $Ca^{2+}$  reabsorptive rates were similar in the distal convolutions in the wild-type and *Slc12a3*-deficient mice [167]. In wild-type mice administered thiazide diuretics, similar observations were made using micropuncture studies, suggesting that the hypocalciuric effect localizes to the proximal tubule [168]. Furthermore, thiazide-induced hypocalciuria can still be observed in *Trpv5*-deficient mice, which effectively lack  $Ca^{2+}$  transport in the distal convolutions [168]. This satisfactorily confirms that the mechanism by which hypocalciuria develops after thiazide usage and probably also in Gitelman's syndrome is independent of distal  $Ca^{2+}$  reabsorption.

Hypomagnesaemia is a consistent feature of Gitelman's syndrome. The phenotypic characteristic is likely to be the result of a decreased abundance of TRPM6, leading to renal  $Mg^{2+}$  wasting. However, the mechanism that decreases renal TRPM6 expression in Gitelman's syndrome remains incompletely understood. Mice deficient in NCC, as well as rats given thiazides, have severe atrophy of the DCT (i.e. the fractional volume of the early DCT is drastically reduced) [167,169]. In addition,

*Slc12a3*-deficient mice have a decreased expression of TRPM6, which localizes intrarenally solely within the DCT [168]. Interestingly, in contrast with previous results, administration of lower doses of thiazides produce no changes in the morphology of the DCT, while the expression of TRPM6 remains decreased [168]. Aldosteronism, a recurring feature of Gitelman's syndrome, has been implicated in renal  $Mg^{2+}$  wasting [170–172]. Similarly, a lack of aldosterone can be associated with hypermagnesaemia [170,171]. Spironolactone, a mineralocorticoid receptor antagonist, has been shown to consistently reduce urinary  $Mg^{2+}$  excretion in a number of patient groups [170,171,173]. In patients with Gitelman's syndrome, spironolactone treatment increases serum  $Mg^{2+}$  concentrations and reduces the fractional tubular excretion of  $Mg^{2+}$  [173]. Thus some studies have suggested that the apparent aldosterone excess observed in Gitelman's syndrome may be an underlying cause. Conversely, chronic infusion of aldosterone does not change the renal mRNA abundance of *Trpm6* in mice [172]. Moreover, marked hyperaldosteronism is observed in patients with antenatal Bartter's syndrome, while less than 20% of these individuals display hypomagnesaemia. The positive effect of spironolactone on  $Mg^{2+}$  balance deserves further research. Currently, the absence of NCC in DCT has been shown to induce hypocalciuria via changes in proximal tubular reabsorption and hypomagnesaemia by reducing TRPM6 expression.

## **TRANSPORT DEFECTS OF THE DISTAL CONVOLUTIONS AFFECTING DIVALENT CATION HANDLING**

### **dRTA (distal renal tubular acidosis)**

Metabolic acidosis caused by an inability of the distal tubule to effectively secrete  $H^+$  ions is referred to as dRTA. dRTA and other types of metabolic acidosis are often accompanied by hypokalaemia, hypercalciuria, nephrocalcinosis and metabolic bone disease. dRTA can be hereditary in an autosomal-dominant fashion or occur as a rarer recessive form which may be associated with sensorineural deafness. The underlying gene defect of dominant dRTA is due to mutations in *SLC4A1* [encoding band 3 erythrocyte AE1 (anion exchanger 1)] [174], whereas mutations in *ATP6V1B1* and *ATP6V0A4* (encoding subunits of the proton pump  $H^+$ -ATPase) cause recessive dRTA with [175] or without [176] sensorineural deafness respectively. It has long been known that metabolic acidosis affects  $Ca^{2+}$  handling. Persistent acidosis is buffered by alkaline salts released from bone, thereby promoting  $Ca^{2+}$  release from the hydroxyapatite crystal. These effects ultimately lead to osteomalacia and osteoporosis and may promote hypercalciuria [177]. Micropuncture experiments, show that distal tubular  $Ca^{2+}$  reabsorption is inhibited by

chronic metabolic acidosis [178], suggesting that renal  $\text{Ca}^{2+}$  wasting is not merely due to  $\text{Ca}^{2+}$  mobilization from bone, but also constitutes an additional renal component. These findings are in good agreement with the observation that the renal expression of TRPV5 is decreased during experimental metabolic acidosis. In line with this, renal  $\text{Ca}^{2+}$  excretion is refractory to  $\text{NH}_4\text{Cl}$ -induced metabolic acidosis in *Trpv5*-deficient mice [179]. Thus the effect of impaired distal secretion of protons and other disturbances (such as renal failure, liver cirrhosis etc.) that cause metabolic acidosis affects the renal tubular transport of  $\text{Ca}^{2+}$ . Interestingly,  $\text{Ca}^{2+}$  influx, probably as the result of acute changes in subcellular distribution and of single channel properties of TRPV5, is regulated by the luminal pH, i.e. acidification of the medium inhibits TRPV5-mediated  $\text{Ca}^{2+}$  reabsorption [180,181]. Thus, during conditions of increased distal tubular proton secretion or delivery (metabolic acidosis due to causes other than dRTA), these TRPV5-specific effects probably also contribute to the observed hypercalciuria.

During dRTA, failure to effectively lower the intraluminal pH in the CNT/CD causes metabolic acidosis. During regular metabolic acidosis, urinary pH becomes more acidic to compensate for the decreased systemic pH; however, hypercalciuria is observed in both conditions. As experimental metabolic acidosis involves a renal component, this probably also occurs in dRTA. This is supported by the observation that most patients with an AE1 defect develop nephrocalcinosis, while few show signs of bone disease (although minor losses from bone could promote  $\text{Ca}^{2+}$  wasting) [174]. Furthermore, acetazolamide induces metabolic acidosis by reducing proximal tubule  $\text{HCO}_3^-$  reabsorption and, hence, increasing urinary pH, a situation similar to dRTA [182]. However, as observed with  $\text{NH}_4\text{Cl}$  treatment, acetazolamide administration causes the down-regulation of TRPV5 in mice, and the hypercalciuria associated with acetazolamide-induced acidosis is absent in *Trpv5*-deficient mice. Hence changes in systemic pH probably promote the down-regulation of renal TRPV5 expression. In contrast, chronic metabolic alkalosis is associated with increased  $\text{Ca}^{2+}$  reabsorption and TRPV5 abundance. However, the  $\text{Ca}^{2+}$ -sparing effect is also observed in *Trpv5*-deficient mice, suggesting that another unknown mechanism is responsible for the increased  $\text{Ca}^{2+}$  reabsorption [179].

In patients with dRTA, serum  $\text{Mg}^{2+}$  concentrations remains unaffected [174,183]; however, children with dRTA present with hypermagnesuria, which can be corrected by  $\text{HCO}_3^-$  administration [183]. Detailed clearance and micropuncture studies have shown that chronic metabolic acidosis causes hypermagnesuria beyond the proximal tubule [184]. Furthermore, chronic metabolic acidosis decreases the renal abundance of TRPM6, whereas metabolic alkalosis has the opposite effect [179]. Acidic pH also augments the inward current of TRPM6,

suggesting that perhaps acute changes in intraluminal pH may affect the channel in an opposite manner from chronic metabolic acidosis. The physiology of this observation is still incompletely understood [132].

### PHAI (pseudohypoaldosteronism type II)

The WNK (with-no-lysine) kinase family consists of serine/threonine kinases with a characteristic displacement of a catalytic lysine residue necessary for ATP binding [185,186]. The identification of the WNK family members as multifunctional proteins required for ambient BP maintenance and renal electrolyte handling has progressively broadened the knowledge of how these processes are regulated [187,188]. PHAI, also known as Gordon's syndrome, is an autosomal-dominant disorder associated with hypertension, an augmented renal reabsorption of  $\text{Na}^+/\text{Cl}^-$  and impaired secretion of  $\text{K}^+$  and  $\text{H}^+$  [188,189]. The genetic defects in PHAI are due to loss-of-function mutations in *WNK4*, as well as activating mutations in *WNK1* caused by intronic deletions [188]. Several studies have now shown that *WNK1* and *WNK4* play important roles in modulating electrolyte transport pathways in the distal convolutions [190–193].

In addition to the often hypertensive phenotype, hypercalciuria and nephrolithiasis has been reported in patients with PHAI [194,195]. Accordingly, individuals carrying a *WNK4* Q565E mutation present with hypercalciuria and a decreased bone mineral density. Conversely, affected members with activating *WNK1* mutations present with normocalciuria [196]. It is interesting to note that no apparent change is observed in serum  $\text{Mg}^{2+}$  concentrations or renal  $\text{Mg}^{2+}$  handling in patients with PHAI [196–198]. The mechanism by which dysfunctional *WNK4* stimulates calciuria in PHAI is unclear, but may occur via several mechanisms.

(i) Secondary to volume expansion, a condition that is predicted to reduce proximal tubule  $\text{Na}^+$  reabsorption, resulting in decreased electrochemical driving force for  $\text{Ca}^{2+}$  uptake across the proximal tubular epithelia [16,168,199]. As the majority of  $\text{Ca}^{2+}$  reabsorption occurs in the proximal tubule, volume expansion might be the largest contributor to hypercalciuria in PHAI. Even so, individuals carrying the *WNK1* deletion have normocalciuria in the presence of elevated BP (and probably an expanded extracellular volume). (ii) Alternatively, the hypercalciuric phenotype in PHAI may be due to impaired interactions between *WNK4* and renal  $\text{Ca}^{2+}$  transport proteins [200]. In line with this, it has been reported that *WNK4* directly activates  $\text{Ca}^{2+}$  transport by increasing the surface expression of TRPV5 in the *Xenopus* oocyte expression system [200]. However, the *WNK4* PHAI mutants showed a similar activating effect on TRPV5. Using lentivirus-induced gene delivery to primary rabbit CNT/cortical CD cells, we found that cells infected with *WNK4* and the *WNK4* Q565E

mutant both decreased transepithelial  $\text{Ca}^{2+}$  transport (H. Dimke, J.G. Hoenderop and R.J. Bindels, unpublished work). Consequently, the exact aetiology underlying hypercalcaemia in PHAII needs further clarification. It is interesting to note that, although PHAII is considered a mirror image of Gitelman's syndrome, no changes in serum  $\text{Mg}^{2+}$  have been observed in these individuals.

## COLLECTING SYSTEM

It is generally accepted that the CD does not contribute significantly to overall renal  $\text{Ca}^{2+}$  transport. Classical micropuncture studies have been aided by determining the fraction of  $\text{Ca}^{2+}$  transport after the distal convolutions, by allowing late distal measurements of cations. On the basis of the observations that (i) relatively little  $\text{K}^+$  secretion is thought to occur in the early distal convolutions comprising the DCT and (ii)  $\text{K}^+$  secretion coupled with increased osmotic water permeability in CNT and accessible CD segments markedly raises luminal  $\text{K}^+$  concentration, it was possible to correlate the fractional delivery of  $\text{Ca}^{2+}$  to the luminal  $\text{K}^+$  concentration at distal puncture sites. As evident from the intrarenal distribution of TRPV5,  $\text{Ca}^{2+}$  delivery decreases with increased luminal  $\text{K}^+$  concentration in wild-type mice. Conversely, in mice with a targeted disruption of the *Trpv5* gene,  $\text{Ca}^{2+}$  delivery was markedly increased with increasing luminal  $\text{K}^+$  concentrations [122]. Results obtained from these experiments and others suggest that very little  $\text{Ca}^{2+}$  (<2%) is delivered to segments of high  $\text{K}^+$  secretion [122,168]. Assuming that the highest luminal  $\text{K}^+$  concentration represents the very latest superficial distal convolutions, negligible  $\text{Ca}^{2+}$  transport must occur in the remainder of the CD. Microperfusion of the granular and light portions of the cortical ducts in the rabbit have suggested that  $\text{Ca}^{2+}$  transport only occurs in the granular portion. Thus the non-superficial segments of the collecting system probably provide a small contribution to overall renal  $\text{Ca}^{2+}$  reabsorption.

The relative contributions of the CD to overall  $\text{Mg}^{2+}$  reabsorption are probably negligible. Estimations from micropuncture studies suggest little  $\text{Mg}^{2+}$  transport after the DCT. Microperfusion of cortical CDs failed to show a significant amount of net  $\text{Mg}^{2+}$  movement [201]. In line with this, microcatheterization studies found no net  $\text{Mg}^{2+}$  transport over the length of the inner medulla CD [202].

## HYPOMAGNEAEMIA, HYPERTENSION AND HYPERCHOLESTEROLAEMIA

A large family was identified with a high prevalence of hypomagnesaemia, hypertension, and hypercholesterolaemia [203]. Interestingly, males with the syndrome did not transmit the phenotype to their offspring.

Conversely, offspring from affected females inherited the trait with high frequency, suggesting mitochondrial transmission. The defect was discovered to be a thymidine-to-cytidine conversion near the anticodon of the isoleucine tRNA. Subjects suffering from hypomagnesaemia had an augmented fractional excretion of  $\text{Mg}^{2+}$ , indicative of renal wasting. Individuals in the maternal lineage also had renal  $\text{Ca}^{2+}$  loss. Hypokalaemia was present in subjects with hypomagnesaemia, perhaps as a consequence of hypomagnesaemia. In one affected member, immunohistochemical and electron microscopic evaluation revealed signs of mitochondrial dysfunction. In line with this, NMR revealed a decreased production of ATP in skeletal muscle [203].

The exact aetiology underlying this disorder remains unclear. The authors suggested that reduced energy production could limit the highly energy consuming DCT and thereby impede transcellular  $\text{Mg}^{2+}$  transport [109]. How large a reduction would be needed to diminish the membrane potential enough to affect  $\text{Mg}^{2+}$  reabsorption in the DCT is unclear; however, the renal  $\text{Na}^+$  excretion remained unchanged between the affected and unaffected family members [203].

## SUMMARY

The necessity of maintaining the systemic concentrations of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  within normal limits is evident, as disturbances in these divalent cations affect important physiological processes. For instance, hypomagnesaemia is a recurrent condition often encountered in the clinical setting. The detailed characterization of the underlying causes of monogenic diseases related to defective renal  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  handling has greatly aided the understanding of how renal and, hence, systemic divalent homeostasis is maintained. Proximal tubular transport defects, such as Dent's disease, can cause hypercalciuria. In the TAL, inadequate, absent or even increased ion transport confers several syndromes, which drastically changes the renal handling of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$ . In addition, vectorial transcellular  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  transport in the distal convolutions can be disturbed as a consequence of changes in the transport of other ions or by directly affecting TRP channel function. An even better understanding of the mechanisms governing the transport of  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  can be obtained by studying these disease conditions or by mimicking these in genetically modified animals.

## ACKNOWLEDGEMENTS

We thank Todd R. Alexander and Tom Nijenhuis for critical reading of the manuscript prior to submission. Erik Ilsø Christensen and Nine Knoers are thanked for helpful comments on the manuscript.

## FUNDING

This work was supported by the Netherlands Organization for Scientific Research [grant number ZonMw 9120.6110]; an EURYI award from the European Science Foundation; the Dutch Kidney Foundation [grant number C05.2134].

## REFERENCES

- Bilezikian, J. P. (1993) Management of hypercalcemia. *J. Clin. Endocrinol. Metab.* **77**, 1445–1449
- Guisse, T. A. and Mundy, G. R. (1995) Clinical review 69: Evaluation of hypocalcemia in children and adults. *J. Clin. Endocrinol. Metab.* **80**, 1473–1478
- Topf, J. M. and Murray, P. T. (2003) Hypomagnesemia and hypermagnesemia. *Rev. Endocr. Metab. Disord.* **4**, 195–206
- Dai, L. J., Ritchie, G., Kerstan, D., Kang, H. S., Cole, D. E. and Quamme, G. A. (2001) Magnesium transport in the renal distal convoluted tubule. *Physiol. Rev.* **81**, 51–84
- Hoenderop, J. G., Nilius, B. and Bindels, R. J. (2005) Calcium absorption across epithelia. *Physiol. Rev.* **85**, 373–422
- Thode, J., Wandrup, J., Aas, F. and Siggaard-Andersen, O. (1982) Evaluation of a new semiautomatic electrode system for simultaneous measurement of ionized calcium and pH. *Scand. J. Clin. Lab. Invest.* **42**, 407–415
- Friedman, P. A. (1988) Renal calcium transport: sites and insights. *News Physiol. Sci.* **3**, 17–20
- Grimellec, C. L., Poujeol, P. and Rouffignac, C. (1975) <sup>3</sup>H-inulin and electrolyte concentrations in Bowman's capsule in rat kidney. Comparison with artificial ultrafiltration. *Pflügers Arch.* **354**, 117–131
- Friedman, P. A. and Gesek, F. A. (1995) Cellular calcium transport in renal epithelia: measurement, mechanisms, and regulation. *Physiol. Rev.* **75**, 429–471
- Lassiter, W. E., Gottschalk, C. W. and Mylle, M. (1963) Micropuncture study of renal tubular reabsorption of calcium in normal rodents. *Am. J. Physiol.* **204**, 771–775
- Suki, W. N. (1979) Calcium transport in the nephron. *Am. J. Physiol.* **237**, F1–F6
- Seldin, D. W. (1999) Renal handling of calcium. *Nephron* **81** (Suppl. 1), 2–7
- Duarte, C. G. and Watson, J. F. (1967) Calcium reabsorption in proximal tubule of the dog nephron. *Am. J. Physiol.* **212**, 1355–1360
- Ng, R. C., Rouse, D. and Suki, W. N. (1984) Calcium transport in the rabbit superficial proximal convoluted tubule. *J. Clin. Invest.* **74**, 834–842
- Le Grimellec, C. (1975) Micropuncture study along the proximal convoluted tubule. Electrolyte reabsorption in first convolutions. *Pflügers Arch.* **354**, 133–150
- Suki, W. N., Schwetzmann, R. S., Rector, Jr, F. C. and Seldin, D. W. (1968) Effect of chronic mineralocorticoid administration on calcium excretion in the rat. *Am. J. Physiol.* **215**, 71–74
- Lowenstein, F. W. and Stanton, M. F. (1986) Serum magnesium levels in the United States, 1971–1974. *J. Am. Coll. Nutr.* **5**, 399–414
- de Rouffignac, C. and Quamme, G. (1994) Renal magnesium handling and its hormonal control. *Physiol. Rev.* **74**, 305–322
- Le Grimellec, C., Roinel, N. and Morel, F. (1973) Simultaneous Mg, Ca, P, K, Na and Cl analysis in rat tubular fluid. I. During perfusion of either inulin or ferrocyanide. *Pflügers Arch.* **340**, 181–196
- Quamme, G. A. (1993) Laboratory evaluation of magnesium status. Renal function and free intracellular magnesium concentration. *Clin. Lab. Med.* **13**, 209–223
- Quamme, G. A., Wong, N. L., Dirks, J. H., Roinel, N., De Rouffignac, C. and Morel, F. (1978) Magnesium handling in the dog kidney: a micropuncture study. *Pflügers Arch.* **377**, 95–99
- Quamme, G. A. and Smith, C. M. (1984) Magnesium transport in the proximal straight tubule of the rabbit. *Am. J. Physiol.* **246**, F544–F550
- Wong, N. L., Whiting, S. J., Mizgala, C. L. and Quamme, G. A. (1986) Electrolyte handling by the superficial nephron of the rabbit. *Am. J. Physiol.* **250**, F590–F595
- LeGievre-Pegorier, M., Merlet-Benichou, C., Roinel, N. and de Rouffignac, C. (1983) Developmental pattern of water and electrolyte transport in rat superficial nephrons. *Am. J. Physiol.* **245**, F15–F21
- Poujeol, P., Chabardes, D., Roinel, N. and De Rouffignac, C. (1976) Influence of extracellular fluid volume expansion on magnesium, calcium and phosphate handling along the rat nephron. *Pflügers Arch.* **365**, 203–211
- Wrong, O. M., Norden, A. G. and Feest, T. G. (1994) Dent's disease; a familial proximal renal tubular syndrome with low-molecular-weight proteinuria, hypercalciuria, nephrocalcinosis, metabolic bone disease, progressive renal failure and a marked male predominance. *Quart. J. Med.* **87**, 473–493
- Pook, M. A., Wrong, O., Wooding, C., Norden, A. G., Feest, T. G. and Thakker, R. V. (1993) Dent's disease, a renal Fanconi syndrome with nephrocalcinosis and kidney stones, is associated with a microdeletion involving DXS255 and maps to Xp11.22. *Hum. Mol. Genet.* **2**, 2129–2134
- Lloyd, S. E., Pearce, S. H., Fisher, S. E., Steinmeyer, K., Schwappach, B., Scheinman, S. J., Harding, B., Bolino, A., Devoto, M., Goodyer, P. et al. (1996) A common molecular basis for three inherited kidney stone diseases. *Nature* **379**, 445–449
- Reinhart, S. C., Norden, A. G., Lapsley, M., Thakker, R. V., Pang, J., Moses, A. M., Frymoyer, P. A., Favus, M. J., Hoepner, J. A. and Scheinman, S. J. (1995) Characterization of carrier females and affected males with X-linked recessive nephrolithiasis. *J. Am. Soc. Nephrol.* **5**, 1451–1461
- Piccolo, A. and Pusch, M. (2005) Chloride/proton antiporter activity of mammalian CLC proteins CLC-4 and CLC-5. *Nature* **436**, 420–423
- Scheel, O., Zdebek, A. A., Lourdel, S. and Jentsch, T. J. (2005) Voltage-dependent electrogenic chloride/proton exchange by endosomal CLC proteins. *Nature* **436**, 424–427
- Devuyst, O., Christie, P. T., Courtoy, P. J., Beauwens, R. and Thakker, R. V. (1999) Intra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent's disease. *Hum. Mol. Genet.* **8**, 247–257
- Christensen, E. I., Devuyst, O., Dom, G., Nielsen, R., Van der Smissen, P., Verroust, P., Leruth, M., Guggino, W. B. and Courtoy, P. J. (2003) Loss of chloride channel CLC-5 impairs endocytosis by defective trafficking of megalin and cubilin in kidney proximal tubules. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 8472–8477
- Piwon, N., Gunther, W., Schwake, M., Bosl, M. R. and Jentsch, T. J. (2000) CLC-5 Cl<sup>-</sup>-channel disruption impairs endocytosis in a mouse model for Dent's disease. *Nature* **408**, 369–373
- Wang, S. S., Devuyst, O., Courtoy, P. J., Wang, X. T., Wang, H., Wang, Y., Thakker, R. V., Guggino, S. and Guggino, W. B. (2000) Mice lacking renal chloride channel, CLC-5, are a model for Dent's disease, a nephrolithiasis disorder associated with defective receptor-mediated endocytosis. *Hum. Mol. Genet.* **9**, 2937–2945
- Yamamoto, K., Cox, J. P., Friedrich, T., Christie, P. T., Bald, M., Houtman, P. N., Lapsley, M. J., Patzer, L., Tsimaratos, M., Van'T Hoff, W. G. et al. (2000) Characterization of renal chloride channel (CLCN5) mutations in Dent's disease. *J. Am. Soc. Nephrol.* **11**, 1460–1468
- Guggino, S. E. (2007) Mechanisms of disease: what can mouse models tell us about the molecular processes underlying Dent disease? *Nat. Clin. Pract. Nephrol.* **3**, 449–455

- 38 Leheste, J. R., Melsen, F., Wellner, M., Jansen, P., Schlichting, U., Renner-Muller, I., Andreassen, T. T., Wolf, E., Bachmann, S., Nykjaer, A. and Willnow, T. E. (2003) Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. *FASEB J.* **17**, 247–249
- 39 Nykjaer, A., Dragun, D., Walther, D., Vorum, H., Jacobsen, C., Herz, J., Melsen, F., Christensen, E. I. and Willnow, T. E. (1999) An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D<sub>3</sub>. *Cell* **96**, 507–515
- 40 Leahey, A. M., Charnas, L. R. and Nussbaum, R. L. (1993) Nonsense mutations in the OCRL-1 gene in patients with the oculocerebrorenal syndrome of Lowe. *Hum. Mol. Genet.* **2**, 461–463
- 41 Zhang, X., Hartz, P. A., Philip, E., Racusen, L. C. and Majerus, P. W. (1998) Cell lines from kidney proximal tubules of a patient with Lowe syndrome lack OCRL inositol polyphosphate 5-phosphatase and accumulate phosphatidylinositol 4,5-bisphosphate. *J. Biol. Chem.* **273**, 1574–1582
- 42 Stechman, M. J., Loh, N. Y. and Thakker, R. V. (2008) Genetic causes of hypercalciuric nephrolithiasis. *Pediatr. Nephrol.*, doi 10.1007/s00467-008-0807-0
- 43 Sliman, G. A., Winters, W. D., Shaw, D. W. and Avner, E. D. (1995) Hypercalciuria and nephrocalcinosis in the oculocerebrorenal syndrome. *J. Urol.* **153**, 1244–1246
- 44 Hoopes, Jr, R. R., Shrimpton, A. E., Knohl, S. J., Hueber, P., Hoppe, B., Matyus, J., Simckes, A., Tasic, V., Toenshoff, B., Suchy, S. F. et al. (2005) Dent disease with mutations in OCRL1. *Am. J. Hum. Genet.* **76**, 260–267
- 45 de Rouffignac, C., Corman, B. and Roinel, N. (1983) Stimulation by antidiuretic hormone of electrolyte tubular reabsorption in rat kidney. *Am. J. Physiol.* **244**, F156–F164
- 46 Shareghi, G. R. and Agus, Z. S. (1982) Magnesium transport in the cortical thick ascending limb of Henle's loop of the rabbit. *J. Clin. Invest.* **69**, 759–769
- 47 De Rouffignac, C., Di Stefano, A., Wittner, M., Roinel, N. and Elalouf, J. M. (1991) Consequences of differential effects of ADH and other peptide hormones on thick ascending limb of mammalian kidney. *Am. J. Physiol.* **260**, R1023–R1035
- 48 Suki, W. N., Rouse, D., Ng, R. C. and Kokko, J. P. (1980) Calcium transport in the thick ascending limb of Henle. Heterogeneity of function in the medullary and cortical segments. *J. Clin. Invest.* **66**, 1004–1009
- 49 Di Stefano, A., Wittner, M., Nitschke, R., Braitsch, R., Greger, R., Bailly, C., Amiel, C., Roinel, N. and de Rouffignac, C. (1990) Effects of parathyroid hormone and calcitonin on Na<sup>+</sup>, Cl<sup>-</sup>, K<sup>+</sup>, Mg<sup>2+</sup> and Ca<sup>2+</sup> transport in cortical and medullary thick ascending limbs of mouse kidney. *Pflugers Arch.* **417**, 161–167
- 50 Burg, M. B. (1976) Tubular chloride transport and the mode of action of some diuretics. *Kidney Int.* **9**, 189–197
- 51 Good, D. W., Knepper, M. A. and Burg, M. B. (1984) Ammonia and bicarbonate transport by thick ascending limb of rat kidney. *Am. J. Physiol.* **247**, F35–F44
- 52 Deschenes, G., Wittner, M., Stefano, A. D., Jounier, S. and Doucet, A. (2001) Collecting duct is a site of sodium retention in PAN nephrosis: a rationale for amiloride therapy. *J. Am. Soc. Nephrol.* **12**, 598–601
- 53 Di Stefano, A., Roinel, N., de Rouffignac, C. and Wittner, M. (1993) Transepithelial Ca<sup>2+</sup> and Mg<sup>2+</sup> transport in the cortical thick ascending limb of Henle's loop of the mouse is a voltage-dependent process. *Renal Physiol. Biochem.* **16**, 157–166
- 54 Quamme, G. A. (1981) Effect of furosemide on calcium and magnesium transport in the rat nephron. *Am. J. Physiol.* **241**, F340–F347
- 55 Greger, R. and Velazquez, H. (1987) The cortical thick ascending limb and early distal convoluted tubule in the urinary concentrating mechanism. *Kidney Int.* **31**, 590–596
- 56 Greger, R. and Schlatter, E. (1983) Properties of the lumen membrane of the cortical thick ascending limb of Henle's loop of rabbit kidney. *Pflugers Arch.* **396**, 315–324
- 57 Greger, R. (1981) Cation selectivity of the isolated perfused cortical thick ascending limb of Henle's loop of rabbit kidney. *Pflugers Arch.* **390**, 30–37
- 58 Rocha, A. S. and Kokko, J. P. (1973) Sodium chloride and water transport in the medullary thick ascending limb of Henle. Evidence for active chloride transport. *J. Clin. Invest.* **52**, 612–623
- 59 Hou, J., Paul, D. L. and Goodenough, D. A. (2005) Paracellin-1 and the modulation of ion selectivity of tight junctions. *J. Cell Sci.* **118**, 5109–5118
- 60 Mandon, B., Siga, E., Roinel, N. and de Rouffignac, C. (1993) Ca<sup>2+</sup>, Mg<sup>2+</sup> and K<sup>+</sup> transport in the cortical and medullary thick ascending limb of the rat nephron: influence of transepithelial voltage. *Pflugers Arch.* **424**, 558–560
- 61 Wittner, M., Mandon, B., Roinel, N., de Rouffignac, C. and Di Stefano, A. (1993) Hormonal stimulation of Ca<sup>2+</sup> and Mg<sup>2+</sup> transport in the cortical thick ascending limb of Henle's loop of the mouse: evidence for a change in the paracellular pathway permeability. *Pflugers Arch.* **423**, 387–396
- 62 Vargas-Poussou, R., Huang, C., Hulin, P., Houillier, P., Jeunemaitre, X., Paillard, M., Planelles, G., Dechaux, M., Miller, R. T. and Antignac, C. (2002) Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. *J. Am. Soc. Nephrol.* **13**, 2259–2266
- 63 Egbuna, O. I. and Brown, E. M. (2008) Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. *Best Pract. Res. Clin. Rheumatol.* **22**, 129–148
- 64 Desfleurs, E., Wittner, M., Simeone, S., Pajaud, S., Moine, G., Rajerison, R. and Di Stefano, A. (1998) Calcium-sensing receptor: regulation of electrolyte transport in the thick ascending limb of Henle's loop. *Kidney Blood Press. Res.* **21**, 401–412
- 65 Motoyama, H. I. and Friedman, P. A. (2002) Calcium-sensing receptor regulation of PTH-dependent calcium absorption by mouse cortical ascending limbs. *Am. J. Physiol. Renal Physiol.* **283**, F399–F406
- 66 McLarnon, S., Holden, D., Ward, D., Jones, M., Elliott, A. and Riccardi, D. (2002) Aminoglycoside antibiotics induce pH-sensitive activation of the calcium-sensing receptor. *Biochem. Biophys. Res. Commun.* **297**, 71–77
- 67 Sassen, M. C., Kim, S. W., Kwon, T. H., Knepper, M. A., Miller, R. T., Frokiaer, J. and Nielsen, S. (2006) Dysregulation of renal sodium transporters in gentamicin-treated rats. *Kidney Int.* **70**, 1026–1037
- 68 Rocha, A. S., Magaldi, J. B. and Kokko, J. P. (1977) Calcium and phosphate transport in isolated segments of rabbit Henle's loop. *J. Clin. Invest.* **59**, 975–983
- 69 Bartter, F. C., Pronove, P., Gill, Jr, J. R. and Maccardie, R. C. (1962) Hyperplasia of the juxtaglomerular complex with hyperaldosteronism and hypokalemic alkalosis. A new syndrome. *Am. J. Med.* **33**, 811–828
- 70 Fanconi, A., Schachenmann, G., Nussli, R. and Prader, A. (1971) Chronic hypokalaemia with growth retardation, normotensive hyperrenin-hyperaldosteronism ('Bartter's syndrome'), and hypercalciuria. Report of two cases with emphasis on natural history and on catch-up growth during treatment. *Helv. Paediatr. Acta* **26**, 144–163
- 71 McCredie, D. A., Rotenberg, E. and Williams, A. L. (1974) Hypercalciuria in potassium-losing nephropathy: a variant of Bartter's syndrome. *Aust. Paediatr. J.* **10**, 286–295
- 72 Simon, D. B., Karet, F. E., Hamdan, J. M., DiPietro, A., Sanjad, S. A. and Lifton, R. P. (1996) Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. *Nat. Genet.* **13**, 183–188
- 73 Simon, D. B., Karet, F. E., Rodriguez-Soriano, J., Hamdan, J. H., DiPietro, A., Trachtman, H., Sanjad, S. A. and Lifton, R. P. (1996) Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K<sup>+</sup> channel, ROMK. *Nat. Genet.* **14**, 152–156
- 74 Kramer, B. K., Bergler, T., Stoelcker, B. and Waldegger, S. (2008) Mechanisms of disease: the kidney-specific chloride channels ClCKA and ClCKB, the Barttin subunit, and their clinical relevance. *Nat. Clin. Pract. Nephrol.* **4**, 38–46

- 75 Konrad, M., Vollmer, M., Lemmink, H. H., van den Heuvel, L. P., Jeck, N., Vargas-Poussou, R., Lakings, A., Ruf, R., Deschenes, G., Antignac, C. et al. (2000) Mutations in the chloride channel gene CLCNKB as a cause of classic Bartter syndrome. *J. Am. Soc. Nephrol.* **11**, 1449–1459
- 76 Greger, R. and Schlatter, E. (1983) Properties of the basolateral membrane of the cortical thick ascending limb of Henle's loop of rabbit kidney. A model for secondary active chloride transport. *Pflügers Arch.* **396**, 325–334
- 77 Simon, D. B., Bindra, R. S., Mansfield, T. A., Nelson-Williams, C., Mendonca, E., Stone, R., Schurman, S., Nayir, A., Alpay, H., Bakkaloglu, A. et al. (1997) Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. *Nat. Genet.* **17**, 171–178
- 78 Birkenhager, R., Otto, E., Schurmann, M. J., Vollmer, M., Ruf, E. M., Maier-Lutz, I., Beekmann, F., Fekete, A., Omran, H., Feldmann, D. et al. (2001) Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. *Nat. Genet.* **29**, 310–314
- 79 Estevez, R., Boettger, T., Stein, V., Birkenhager, R., Otto, E., Hildebrandt, F. and Jentsch, T. J. (2001) Barttin is a Cl<sup>-</sup> channel beta-subunit crucial for renal Cl<sup>-</sup> reabsorption and inner ear K<sup>+</sup> secretion. *Nature* **414**, 558–561
- 80 Schlingmann, K. P., Konrad, M., Jeck, N., Waldegger, P., Reinalter, S. C., Holder, M., Seyberth, H. W. and Waldegger, S. (2004) Salt wasting and deafness resulting from mutations in two chloride channels. *N. Engl. J. Med.* **350**, 1314–1319
- 81 Landau, D., Shaley, H., Ohaly, M. and Carmi, R. (1995) Infantile variant of Bartter syndrome and sensorineural deafness: a new autosomal recessive disorder. *Am. J. Med. Genet* **59**, 454–459
- 82 Pearce, S. H., Williamson, C., Kifor, O., Bai, M., Coulthard, M. G., Davies, M., Lewis-Barned, N., McCredie, D., Powell, H., Kendall-Taylor, P. et al. (1996) A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. *N. Engl. J. Med.* **335**, 1115–1122
- 83 Pollak, M. R., Brown, E. M., Estep, H. L., McLaine, P. N., Kifor, O., Park, J., Hebert, S. C., Seidman, C. E. and Seidman, J. G. (1994) Autosomal dominant hypocalcaemia caused by a Ca<sup>2+</sup>-sensing receptor gene mutation. *Nat. Genet.* **8**, 303–307
- 84 Watanabe, S., Fukumoto, S., Chang, H., Takeuchi, Y., Hasegawa, Y., Okazaki, R., Chikatsu, N. and Fujita, T. (2002) Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. *Lancet* **360**, 692–694
- 85 Jeck, N., Konrad, M., Peters, M., Weber, S., Bonzel, K. E. and Seyberth, H. W. (2000) Mutations in the chloride channel gene, CLCNKB, leading to a mixed Bartter-Gitelman phenotype. *Pediatr. Res.* **48**, 754–758
- 86 Michelis, M. F., Drash, A. L., Linarelli, L. G., De Rubertis, F. R. and Davis, B. B. (1972) Decreased bicarbonate threshold and renal magnesium wasting in a sibship with distal renal tubular acidosis. Evaluation of the pathophysiological role of parathyroid hormone. *Metab., Clin. Exp.* **21**, 905–920
- 87 Praga, M., Vara, J., Gonzalez-Parra, E., Andres, A., Alamo, C., Araque, A., Ortiz, A. and Rodicio, J. L. (1995) Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *Kidney Int.* **47**, 1419–1425
- 88 Simon, D. B., Lu, Y., Choate, K. A., Velazquez, H., Al-Sabban, E., Praga, M., Casari, G., Bettinelli, A., Colussi, G., Rodriguez-Soriano, J. et al. (1999) Paracellin-1, a renal tight junction protein required for paracellular Mg<sup>2+</sup> resorption. *Science* **285**, 103–106
- 89 Konrad, M., Schaller, A., Seelow, D., Pandey, A. V., Waldegger, S., Lesslauer, A., Vitzthum, H., Suzuki, Y., Luk, J. M., Becker, C. et al. (2006) Mutations in the tight-junction gene claudin 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. *Am. J. Hum. Genet.* **79**, 949–957
- 90 Kiuchi-Saishin, Y., Gotoh, S., Furuse, M., Takasuga, A., Tano, Y. and Tsukita, S. (2002) Differential expression patterns of claudins, tight junction membrane proteins, in mouse nephron segments. *J. Am. Soc. Nephrol.* **13**, 875–886
- 91 Weber, S., Schneider, L., Peters, M., Misselwitz, J., Ronnefarth, G., Boswald, M., Bonzel, K. E., Seeman, T., Sulakova, T., Kuwertz-Broking, E. et al. (2001) Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J. Am. Soc. Nephrol.* **12**, 1872–1881
- 92 Muller, D., Kausalya, P. J., Claverie-Martin, F., Meij, I. C., Eggert, P., Garcia-Nieto, V. and Hunziker, W. (2003) A novel claudin 16 mutation associated with childhood hypercalciuria abolishes binding to ZO-1 and results in lysosomal mistargeting. *Am. J. Hum. Genet.* **73**, 1293–1301
- 93 Ikari, A., Matsumoto, S., Harada, H., Takagi, K., Hayashi, H., Suzuki, Y., Degawa, M. and Miwa, M. (2006) Phosphorylation of paracellin-1 at Ser217 by protein kinase A is essential for localization in tight junctions. *J. Cell Sci.* **119**, 1781–1789
- 94 Gunzel, D. and Yu, A. S. (2009) Function and regulation of claudins in the thick ascending limb of Henle. *Pflügers Arch.* **133**, 111–127
- 95 Hou, J., Renigunta, A., Konrad, M., Gomes, A. S., Schneeberger, E. E., Paul, D. L., Waldegger, S. and Goodenough, D. A. (2008) Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. *J. Clin. Invest.* **118**, 619–628
- 96 Di Stefano, A., Wittner, M., Gebler, B. and Greger, R. (1988) Increased Ca<sup>++</sup> or Mg<sup>++</sup> concentration reduces relative tight-junction permeability to Na<sup>+</sup> in the cortical thick ascending limb of Henle's loop of rabbit kidney. *Renal Physiol. Biochem.* **11**, 70–79
- 97 Hou, J., Shan, Q., Wang, T., Gomes, A. S., Yan, Q., Paul, D. L., Bleich, M. and Goodenough, D. A. (2007) Transgenic RNAi depletion of claudin-16 and the renal handling of magnesium. *J. Biol. Chem.* **282**, 17114–17122
- 98 Blanchard, A., Jeunemaitre, X., Coudol, P., Dechaux, M., Froissart, M., May, A., Demontis, R., Fournier, A., Paillard, M. and Houillier, P. (2001) Paracellin-1 is critical for magnesium and calcium reabsorption in the human thick ascending limb of Henle. *Kidney Int.* **59**, 2206–2215
- 99 Himmerkus, N., Shan, Q., Goerke, B., Hou, J., Goodenough, D. A. and Bleich, M. (2008) Salt and acid-base metabolism in claudin-16 knockdown mice: impact for the pathophysiology of FHHNC patients. *Am. J. Physiol. Renal Physiol.* **295**, F1641–F1647
- 100 Marx, S. J., Spiegel, A. M., Brown, E. M., Koehler, J. O., Gardner, D. G., Brennan, M. F. and Aurbach, G. D. (1978) Divalent cation metabolism. Familial hypocalciuric hypercalcemia versus typical primary hyperparathyroidism. *Am. J. Med.* **65**, 235–242
- 101 Heath, III, H. (1989) Familial benign (hypocalciuric) hypercalcemia. A troublesome mimic of mild primary hyperparathyroidism. *Endocrinol. Metab. Clin. N. Am.* **18**, 723–740
- 102 Auwerx, J., Demedts, M. and Bouillon, R. (1984) Altered parathyroid set point to calcium in familial hypocalciuric hypercalcaemia. *Acta Endocrinol.* **106**, 215–218
- 103 Attie, M. F., Gill, Jr, J. R., Stock, J. L., Spiegel, A. M., Downs, Jr, R. W., Levine, M. A. and Marx, S. J. (1983) Urinary calcium excretion in familial hypocalciuric hypercalcemia. Persistence of relative hypocalciuria after induction of hypoparathyroidism. *J. Clin. Invest.* **72**, 667–676
- 104 Law, Jr, W. M. and Heath, III, H. (1985) Familial benign hypercalcemia (hypocalciuric hypercalcemia). Clinical and pathogenetic studies in 21 families. *Ann. Intern. Med.* **102**, 511–519
- 105 Marx, S. J., Fraser, D. and Rapoport, A. (1985) Familial hypocalciuric hypercalcemia. Mild expression of the gene in heterozygotes and severe expression in homozygotes. *Am. J. Med.* **78**, 15–22
- 106 Hebert, S. C. (1996) Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. *Kidney Int.* **50**, 2129–2139
- 107 Kos, C. H., Karaplis, A. C., Peng, J. B., Hediger, M. A., Goltzman, D., Mohammedi, K. S., Guise, T. A. and Pollak, M. R. (2003) The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. *J. Clin. Invest.* **111**, 1021–1028



- 108 Kriz, W. and Bankir, L. (1988) A standard nomenclature for structures of the kidney. The Renal Commission of the International Union of Physiological Sciences (IUPS). *Kidney Int.* **33**, 1–7
- 109 Reilly, R. F. and Ellison, D. H. (2000) Mammalian distal tubule: physiology, pathophysiology, and molecular anatomy. *Physiol. Rev.* **80**, 277–313
- 110 Malnic, G. and Giebisch, G. (1972) Some electrical properties of distal tubular epithelium in the rat. *Am. J. Physiol.* **223**, 797–808
- 111 Wright, F. S. (1971) Increasing magnitude of electrical potential along the renal distal tubule. *Am. J. Physiol.* **220**, 624–638
- 112 Giebisch, G., Malnic, G., Klose, R. M. and Windhager, E. E. (1966) Effect of ionic substitutions on distal potential differences in rat kidney. *Am. J. Physiol.* **211**, 560–568
- 113 Solomon, S. (1957) Transtubular potential differences of rat kidney. *J. Cell. Physiol.* **49**, 351–365
- 114 Agus, Z. S., Chiu, P. J. and Goldberg, M. (1977) Regulation of urinary calcium excretion in the rat. *Am. J. Physiol.* **232**, F545–F549
- 115 Bailly, C., Roinel, N. and Amiel, C. (1985) Stimulation by glucagon and PTH of Ca and Mg reabsorption in the superficial distal tubule of the rat kidney. *Pflügers Arch.* **403**, 28–34
- 116 Hoenderop, J. G., van der Kemp, A. W., Hartog, A., van de Graaf, S. F., van Os, C. H., Willems, P. H. and Bindels, R. J. (1999) Molecular identification of the apical  $\text{Ca}^{2+}$  channel in 1, 25-dihydroxyvitamin D<sub>3</sub>-responsive epithelia. *J. Biol. Chem.* **274**, 8375–8378
- 117 Hoenderop, J. G., Hartog, A., Stuiver, M., Doucet, A., Willems, P. H. and Bindels, R. J. (2000) Localization of the epithelial  $\text{Ca}^{2+}$  channel in rabbit kidney and intestine. *J. Am. Soc. Nephrol.* **11**, 1171–1178
- 118 Loffing, J. and Kaissling, B. (2003) Sodium and calcium transport pathways along the mammalian distal nephron: from rabbit to human. *Am. J. Physiol. Renal Physiol.* **284**, F628–F643
- 119 Hoenderop, J. G., Muller, D., Van Der Kemp, A. W., Hartog, A., Suzuki, M., Ishibashi, K., Imai, M., Sweep, F., Willems, P. H., Van Os, C. H. and Bindels, R. J. (2001) Calcitriol controls the epithelial calcium channel in kidney. *J. Am. Soc. Nephrol.* **12**, 1342–1349
- 120 Hofmeister, M. V., Fenton, R. A. and Praetorius, J. (2009) Fluorescence-isolation of mouse late distal convoluted tubules and connecting tubules: effects of vasopressin and vitamin D<sub>3</sub> on  $\text{Ca}^{2+}$  signaling. *Am. J. Physiol. Renal Physiol.* **296**, F194–F203
- 121 Loffing, J., Loffing-Cueni, D., Valderrabano, V., Klausli, L., Hebert, S. C., Rossier, B. C., Hoenderop, J. G., Bindels, R. J. and Kaissling, B. (2001) Distribution of transcellular calcium and sodium transport pathways along mouse distal nephron. *Am. J. Physiol. Renal Physiol.* **281**, F1021–F1027
- 122 Hoenderop, J. G., van Leeuwen, J. P., van der Eerden, B. C., Kersten, F. F., van der Kemp, A. W., Merillat, A. M., Waarsing, J. H., Rossier, B. C., Vallon, V., Hummler, E. and Bindels, R. J. (2003) Renal  $\text{Ca}^{2+}$  wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. *J. Clin. Invest.* **112**, 1906–1914
- 123 Renkema, K. Y., Lee, K., Topala, C. N., Goossens, M., Houillier, P., Bindels, R. J. and Hoenderop, J. G. (2009) TRPV5 gene polymorphisms in renal hypercalciuria. *Nephrol. Dial. Transplant.* **24**, 1919–1924
- 124 Brunette, M. G., Vigneault, N. and Carriere, S. (1974) Micropuncture study of magnesium transport along the nephron in the young rat. *Am. J. Physiol.* **227**, 891–896
- 125 Quamme, G. A. and Dirks, J. H. (1980) Intraluminal and contraluminal magnesium on magnesium and calcium transfer in the rat nephron. *Am. J. Physiol.* **238**, F187–F198
- 126 Grubbs, R. D. (2002) Intracellular magnesium and magnesium buffering. *Biometals* **15**, 251–259
- 127 Quamme, G. A. and Dai, L. J. (1990) Presence of a novel influx pathway for  $\text{Mg}^{2+}$  in MDCK cells. *Am. J. Physiol.* **259**, C521–C525
- 128 Cohen, B., Giebisch, G., Hansen, L. L., Teuscher, U. and Wiederholt, M. (1984) Relationship between peritubular membrane potential and net fluid reabsorption in the distal renal tubule of Amphiuma. *J. Physiol.* **348**, 115–134
- 129 Hansen, L. L., Schilling, A. R. and Wiederholt, M. (1981) Effect of calcium, furosemide and chlorothiazide on net volume reabsorption and basolateral membrane potential of the distal tubule. *Pflügers Arch.* **389**, 121–126
- 130 Voets, T., Nilius, B., Hoefs, S., van der Kemp, A. W., Droogmans, G., Bindels, R. J. and Hoenderop, J. G. (2004) TRPM6 forms the  $\text{Mg}^{2+}$  influx channel involved in intestinal and renal  $\text{Mg}^{2+}$  absorption. *J. Biol. Chem.* **279**, 19–25
- 131 Montell, C. (2003)  $\text{Mg}^{2+}$  homeostasis: the  $\text{Mg}^{2+}$  nificent TRPM channels. *Curr. Biol.* **13**, R799–R801
- 132 Li, M., Jiang, J. and Yue, L. (2006) Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. *J. Gen. Physiol.* **127**, 525–537
- 133 Li, M., Du, J., Jiang, J., Ratzan, W., Su, L. T., Runnels, L. W. and Yue, L. (2007) Molecular determinants of  $\text{Mg}^{2+}$  and  $\text{Ca}^{2+}$  permeability and pH sensitivity in TRPM6 and TRPM7. *J. Biol. Chem.* **282**, 25817–25830
- 134 Chubanov, V., Schlingmann, K. P., Waring, J., Heinzinger, J., Kaske, S., Waldegger, S., Schnitzler, M. M. and Gudermann, T. (2007) Hypomagnesemia with secondary hypocalcemia due to a missense mutation in the putative pore-forming region of TRPM6. *J. Biol. Chem.* **282**, 7656–7667
- 135 Chubanov, V., Waldegger, S., Mederos y Schnitzler, M., Vitzthum, H., Sassen, M. C., Seyberth, H. W., Konrad, M. and Gudermann, T. (2004) Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia. *Proc. Natl. Acad. Sci. U.S.A.* **101**, 2894–2899
- 136 Schlingmann, K. P. and Gudermann, T. (2005) A critical role of TRPM channel-kinase for human magnesium transport. *J. Physiol.* **566**, 301–308
- 137 Schmitz, C., Dorovkov, M. V., Zhao, X., Davenport, B. J., Ryzanov, A. G. and Perraud, A. L. (2005) The channel kinases TRPM6 and TRPM7 are functionally nonredundant. *J. Biol. Chem.* **280**, 37763–37771
- 138 Groenestege, W. M., Hoenderop, J. G., van den Heuvel, L., Knoers, N. and Bindels, R. J. (2006) The epithelial  $\text{Mg}^{2+}$  channel transient receptor potential melastatin 6 is regulated by dietary  $\text{Mg}^{2+}$  content and estrogens. *J. Am. Soc. Nephrol.* **17**, 1035–1043
- 139 Schlingmann, K. P., Weber, S., Peters, M., Niemann Nejsum, L., Vitzthum, H., Klingel, K., Kratz, M., Haddad, E., Ristoff, E. et al. (2002) Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. *Nat. Genet.* **31**, 166–170
- 140 Walder, R. Y., Landau, D., Meyer, P., Shalev, H., Tsolia, M., Borochowitz, Z., Boettger, M. B., Beck, G. E., Englehardt, R. K., Carmi, R. and Sheffield, V. C. (2002) Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. *Nat. Genet.* **31**, 171–174
- 141 Paunier, L., Radde, I. C., Kooh, S. W., Conen, P. E. and Fraser, D. (1968) Primary hypomagnesemia with secondary hypocalcemia in an infant. *Pediatrics* **41**, 385–402
- 142 Shalev, H., Phillip, M., Galil, A., Carmi, R. and Landau, D. (1998) Clinical presentation and outcome in primary familial hypomagnesaemia. *Arch. Dis. Child.* **78**, 127–130
- 143 Milla, P. J., Aggett, P. J., Wolff, O. H. and Harries, J. T. (1979) Studies in primary hypomagnesaemia: evidence for defective carrier-mediated small intestinal transport of magnesium. *Gut* **20**, 1028–1033
- 144 Stromme, J. H., Steen-Johnsen, J., Harnaes, K., Hofstad, F. and Brandtzaeg, P. (1981) Familial hypomagnesaemia—a follow-up examination of three patients after 9 to 12 years of treatment. *Pediatr. Res.* **15**, 1134–1139
- 145 Matzkin, H., Lotan, D. and Boichis, H. (1989) Primary hypomagnesaemia with a probable double magnesium transport defect. *Nephron* **52**, 83–86
- 146 Agus, Z. S. (1999) Hypomagnesemia. *J. Am. Soc. Nephrol.* **10**, 1616–1622

- 147 Geven, W. B., Monnens, L. A., Willems, J. L., Buijs, W. and Hamel, C. J. (1987) Isolated autosomal recessive renal magnesium loss in two sisters. *Clin. Genet.* **32**, 398–402
- 148 Groenestege, W. M., Thebault, S., van der Wijst, J., van den Berg, D., Janssen, R., Tejpar, S., van den Heuvel, L. P., van Cutsem, E., Hoenderop, J. G., Knoers, N. V. and Bindels, R. J. (2007) Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. *J. Clin. Invest.* **117**, 2260–2267
- 149 Thebault, S., Alexander, R. T., Tiel Groenestege, W. M., Hoenderop, J. G. and Bindels, R. J. (2008) EGF increases TRPM6 activity and surface expression. *J. Am. Soc. Nephrol.* **20**, 78–85
- 150 Tejpar, S., Piessevaux, H., Claes, K., Piront, P., Hoenderop, J. G., Verslype, C. and Van Cutsem, E. (2007) Magnesium wasting associated with epidermal-growth-factor receptor-targeting antibodies in colorectal cancer: a prospective study. *Lancet Oncol.* **8**, 387–394
- 151 Geven, W. B., Monnens, L. A., Willems, H. L., Buijs, W. C. and ter Haar, B. G. (1987) Renal magnesium wasting in two families with autosomal dominant inheritance. *Kidney Int.* **31**, 1140–1144
- 152 Arystarkhova, E., Wetzel, R. K., Asinovski, N. K. and Sweadner, K. J. (1999) The  $\gamma$  subunit modulates Na<sup>+</sup> and K<sup>+</sup> affinity of the renal Na,K-ATPase. *J. Biol. Chem.* **274**, 33183–33185
- 153 Arystarkhova, E., Wetzel, R. K. and Sweadner, K. J. (2002) Distribution and oligomeric association of splice forms of Na<sup>+</sup>-K<sup>+</sup>-ATPase regulatory  $\gamma$ -subunit in rat kidney. *Am. J. Physiol. Renal Physiol.* **282**, F393–F407
- 154 Jones, D. H., Li, T. Y., Arystarkhova, E., Barr, K. J., Wetzel, R. K., Peng, J., Markham, K., Sweadner, K. J., Fong, G. H. and Kidder, G. M. (2005) Na,K-ATPase from mice lacking the gamma subunit (FXVD2) exhibits altered Na<sup>+</sup> affinity and decreased thermal stability. *J. Biol. Chem.* **280**, 19003–19011
- 155 Wetzel, R. K. and Sweadner, K. J. (2001) Immunocytochemical localization of Na-K-ATPase  $\alpha$ - and  $\gamma$ -subunits in rat kidney. *Am. J. Physiol. Renal Physiol.* **281**, F531–F545
- 156 Beguin, P., Crambert, G., Guennoun, S., Garty, H., Horisberger, J. D. and Geering, K. (2001) CHIF, a member of the FXVD protein family, is a regulator of Na,K-ATPase distinct from the  $\gamma$ -subunit. *EMBO J.* **20**, 3993–4002
- 157 Beguin, P., Wang, X., Firsov, D., Puoti, A., Claeys, D., Horisberger, J. D. and Geering, K. (1997) The  $\gamma$  subunit is a specific component of the Na,K-ATPase and modulates its transport function. *EMBO J.* **16**, 4250–4260
- 158 Meij, I. C., Koenderink, J. B., van Bokhoven, H., Assink, K. F., Groenestege, W. T., de Pont, J. J., Bindels, R. J., Monnens, L. A., van den Heuvel, L. P. and Knoers, N. V. (2000) Dominant isolated renal magnesium loss is caused by misrouting of the Na<sup>+</sup>,K<sup>+</sup>-ATPase  $\gamma$ -subunit. *Nat. Genet.* **26**, 265–266
- 159 Cairo, E. R., Friedrich, T., Swarts, H. G., Knoers, N. V., Bindels, R. J., Monnens, L. A., Willems, P. H., De Pont, J. J. and Koenderink, J. B. (2008) Impaired routing of wild type FXVD2 after oligomerisation with FXVD2-G41R might explain the dominant nature of renal hypomagnesemia. *Biochim. Biophys. Acta* **1778**, 398–404
- 160 Sha, Q., Pearson, W., Burcea, L. C., Wigfall, D. A., Schlesinger, P. H., Nichols, C. G. and Mercer, R. W. (2008) Human FXVD2 G41R mutation responsible for renal hypomagnesemia behaves as an inward-rectifying cation channel. *Am. J. Physiol. Renal Physiol.* **295**, F91–F99
- 161 Gitelman, H. J., Graham, J. B. and Welt, L. G. (1966) A new familial disorder characterized by hypokalemia and hypomagnesemia. *Trans. Assoc. Am. Physicians* **79**, 221–235
- 162 Simon, D. B., Nelson-Williams, C., Bia, M. J., Ellison, D., Karet, F. E., Molina, A. M., Vaara, I., Iwata, F., Cushner, H. M., Koolen, M. et al. (1996) Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. *Nat. Genet.* **12**, 24–30
- 163 Costanzo, L. S., Windhager, E. E. and Ellison, D. H. (1978) Calcium and sodium transport by the distal convoluted tubule of the rat. *J. Am. Soc. Nephrol.* **11**, 1562–1580
- 164 Moore, M. J. (1978) Thiazide-induced hypomagnesemia. *JAMA, J. Am. Med. Assoc.* **240**, 1241
- 165 Friedman, P. A. (1998) Codependence of renal calcium and sodium transport. *Annu. Rev. Physiol.* **60**, 179–197
- 166 Nijenhuis, T., Hoenderop, J. G., Loffing, J., van der Kemp, A. W., van Os, C. H. and Bindels, R. J. (2003) Thiazide-induced hypocalciuria is accompanied by a decreased expression of Ca<sup>2+</sup> transport proteins in kidney. *Kidney Int.* **64**, 555–564
- 167 Loffing, J., Vallon, V., Loffing-Cueni, D., Aregger, F., Richter, K., Pietri, L., Bloch-Faure, M., Hoenderop, J. G., Shull, G. E., Meneton, P. and Kaissling, B. (2004) Altered renal distal tubule structure and renal Na<sup>+</sup> and Ca<sup>2+</sup> handling in a mouse model for Gitelman's syndrome. *J. Am. Soc. Nephrol.* **15**, 2276–2288
- 168 Nijenhuis, T., Vallon, V., van der Kemp, A. W., Loffing, J., Hoenderop, J. G. and Bindels, R. J. (2005) Enhanced passive Ca<sup>2+</sup> reabsorption and reduced Mg<sup>2+</sup> channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. *J. Clin. Invest.* **115**, 1651–1658
- 169 Loffing, J., Loffing-Cueni, D., Hegyi, I., Kaplan, M. R., Hebert, S. C., Le Hir, M. and Kaissling, B. (1996) Thiazide treatment of rats provokes apoptosis in distal tubule cells. *Kidney Int.* **50**, 1180–1190
- 170 Horton, R. and Biglieri, E. G. (1962) Effect of aldosterone on the metabolism of magnesium. *J. Clin. Endocrinol. Metab.* **22**, 1187–1192
- 171 Ellison, D. H. (2000) Divalent cation transport by the distal nephron: insights from Bartter's and Gitelman's syndromes. *Am. J. Physiol. Renal Physiol.* **279**, F616–F625
- 172 Sontia, B., Montezano, A. C., Paravicini, T., Tabet, F. and Touyz, R. M. (2008) Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. *Hypertension* **51**, 915–921
- 173 Colussi, G., Rombola, G., De Ferrari, M. E., Macaluso, M. and Minetti, L. (1994) Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. *Am. J. Nephrol.* **14**, 127–135
- 174 Bruce, L. J., Cope, D. L., Jones, G. K., Schofield, A. E., Burley, M., Povey, S., Unwin, R. J., Wrong, O. and Tanner, M. J. (1997) Familial distal renal tubular acidosis is associated with mutations in the red cell anion exchanger (Band 3, AE1) gene. *J. Clin. Invest.* **100**, 1693–1707
- 175 Karet, F. E., Finberg, K. E., Nelson, R. D., Nayir, A., Mocan, H., Sanjad, S. A., Rodriguez-Soriano, J., Santos, F., Cremers, C. W., Di Pietro, A. et al. (1999) Mutations in the gene encoding B1 subunit of H<sup>+</sup>-ATPase cause renal tubular acidosis with sensorineural deafness. *Nat. Genet.* **21**, 84–90
- 176 Smith, A. N., Skaug, J., Choate, K. A., Nayir, A., Bakkaloglu, A., Ozen, S., Hulton, S. A., Sanjad, S. A., Al-Sabban, E. A., Lifton, R. P. et al. (2000) Mutations in ATP6N1B, encoding a new kidney vacuolar proton pump 116-kD subunit, cause recessive distal renal tubular acidosis with preserved hearing. *Nat. Genet.* **26**, 71–75
- 177 Lemann, Jr, J., Bushinsky, D. A. and Hamm, L. L. (2003) Bone buffering of acid and base in humans. *Am. J. Physiol. Renal Physiol.* **285**, F811–F832
- 178 Sutton, R. A., Wong, N. L. and Dirks, J. H. (1979) Effects of metabolic acidosis and alkalosis on sodium and calcium transport in the dog kidney. *Kidney Int.* **15**, 520–533
- 179 Nijenhuis, T., Renkema, K. Y., Hoenderop, J. G. and Bindels, R. J. (2006) Acid-base status determines the renal expression of Ca<sup>2+</sup> and Mg<sup>2+</sup> transport proteins. *J. Am. Soc. Nephrol.* **17**, 617–626
- 180 Lambers, T. T., Oancea, E., de Groot, T., Topala, C. N., Hoenderop, J. G. and Bindels, R. J. (2007) Extracellular pH dynamically controls cell surface delivery of functional TRPV5 channels. *Mol. Cell. Biol.* **27**, 1486–1494

- 181 Yeh, B. I., Sun, T. J., Lee, J. Z., Chen, H. H. and Huang, C. L. (2003) Mechanism and molecular determinant for regulation of rabbit transient receptor potential type 5 (TRPV5) channel by extracellular pH. *J. Biol. Chem.* **278**, 51044–51052
- 182 Dirks, J. H., Cirksena, W. J. and Berliner, R. W. (1966) Micropuncture study of the effect of various diuretics on sodium reabsorption by the proximal tubules of the dog. *J. Clin. Invest.* **45**, 1875–1885
- 183 Ariceta, G., Vallo, A. and Rodriguez-Soriano, J. (2004) Acidosis increases magnesiumuria in children with distal renal tubular acidosis. *Pediatr. Nephrol.* **19**, 1367–1370
- 184 Wong, N. L., Quamme, G. A. and Dirks, J. H. (1986) Effects of acid-base disturbances on renal handling of magnesium in the dog. *Clin. Sci.* **70**, 277–284
- 185 Xu, B., English, J. M., Wilsbacher, J. L., Stippec, S., Goldsmith, E. J. and Cobb, M. H. (2000) WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II. *J. Biol. Chem.* **275**, 16795–16801
- 186 Verissimo, F. and Jordan, P. (2001) WNK kinases, a novel protein kinase subfamily in multi-cellular organisms. *Oncogene* **20**, 5562–5569
- 187 Zambrowicz, B. P., Abuin, A., Ramirez-Solis, R., Richter, L. J., Piggott, J., BeltrandelRio, H., Buxton, E. C., Edwards, J., Finch, R. A., Friddle, C. J. et al. (2003) Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. *Proc. Natl. Acad. Sci. U.S.A.* **100**, 14109–14114
- 188 Wilson, F. H., Disse-Nicodeme, S., Choate, K. A., Ishikawa, K., Nelson-Williams, C., Desitter, I., Gunel, M., Milford, D. V., Lipkin, G. W., Achard, J. M. et al. (2001) Human hypertension caused by mutations in WNK kinases. *Science* **293**, 1107–1112
- 189 Gordon, R. D. (1986) The syndrome of hypertension and hyperkalemia with normal glomerular filtration rate: Gordon's syndrome. *Aust. NZ J. Med.* **16**, 183–184
- 190 Yang, C. L., Angell, J., Mitchell, R. and Ellison, D. H. (2003) WNK kinases regulate thiazide-sensitive Na-Cl cotransport. *J. Clin. Invest.* **111**, 1039–1045
- 191 Kahle, K. T., Wilson, F. H., Leng, Q., Lalioti, M. D., O'Connell, A. D., Dong, K., Rapson, A. K., MacGregor, G. G., Giebisch, G., Hebert, S. C. and Lifton, R. P. (2003) WNK4 regulates the balance between renal Na<sup>+</sup>/Cl<sup>-</sup> reabsorption and K<sup>+</sup> secretion. *Nat. Genet.* **35**, 372–376
- 192 Lazrak, A., Liu, Z. and Huang, C. L. (2006) Antagonistic regulation of ROMK by long and kidney-specific WNK1 isoforms. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 1615–1620
- 193 Yang, C. L., Zhu, X. and Ellison, D. H. (2007) The thiazide-sensitive Na-Cl cotransporter is regulated by a WNK kinase signaling complex. *J. Clin. Invest.* **117**, 3403–3411
- 194 Rodriguez-Soriano, J., Vallo, A. and Dominguez, M. J. (1989) 'Chloride-shunt' syndrome: an overlooked cause of renal hypercalciuria. *Pediatr. Nephrol.* **3**, 113–121
- 195 Stratton, J. D., McNicholas, T. A. and Farrington, K. (1998) Recurrent calcium stones in Gordon's syndrome. *Br. J. Urol.* **82**, 925
- 196 Achard, J. M., Warnock, D. G., Disse-Nicodeme, S., Fiquet-Kempf, B., Corvol, P., Fournier, A. and Jeunemaitre, X. (2003) Familial hyperkalemic hypertension: phenotypic analysis in a large family with the WNK1 deletion mutation. *Am. J. Med.* **114**, 495–498
- 197 Mayan, H., Vered, I., Mouallem, M., Tzadok-Witkon, M., Puzner, R. and Farfel, Z. (2002) Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. *J. Clin. Endocrinol. Metab.* **87**, 3248–3254
- 198 Mayan, H., Munter, G., Shaharabany, M., Mouallem, M., Puzner, R., Holtzman, E. J. and Farfel, Z. (2004) Hypercalciuria in familial hyperkalemia and hypertension accompanies hyperkalemia and precedes hypertension: description of a large family with the Q565E WNK4 mutation. *J. Clin. Endocrinol. Metab.* **89**, 4025–4030
- 199 Lau, K. and Eby, B. K. (1982) Tubular mechanism for the spontaneous hypercalciuria in laboratory rat. *J. Clin. Invest.* **70**, 835–844
- 200 Jiang, Y., Ferguson, W. B. and Peng, J. B. (2007) WNK4 enhances TRPV5-mediated calcium transport: potential role in hypercalciuria of familial hyperkalemic hypertension caused by gene mutation of WNK4. *Am. J. Physiol. Renal Physiol.* F545–F554
- 201 Shareghi, G. R. and Agus, Z. S. (1982) Phosphate transport in the light segment of the rabbit cortical collecting tubule. *Am. J. Physiol.* **242**, F379–F384
- 202 Bengele, H. H., Alexander, E. A. and Lechene, C. P. (1980) Calcium and magnesium transport along the inner medullary collecting duct of the rat. *Am. J. Physiol.* **239**, F24–F29
- 203 Wilson, F. H., Hariri, A., Farhi, A., Zhao, H., Petersen, K. F., Toka, H. R., Nelson-Williams, C., Raja, K. M., Kashgarian, M., Shulman, G. I. et al. (2004) A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. *Science* **306**, 1190–1194
- 204 Barratt, L. J., Rector, Jr, F. C., Kokko, J. P. and Seldin, D. W. (1974) Factors governing the transepithelial potential difference across the proximal tubule of the rat kidney. *J. Clin. Invest.* **53**, 454–464

Received 10 February 2009/1 April 2009; accepted 23 April 2009  
Published on the Internet 28 September 2009, doi:10.1042/CS20090086